US20070016256A1 - Method and apparatus for treating gland dysfunction - Google Patents

Method and apparatus for treating gland dysfunction Download PDF

Info

Publication number
US20070016256A1
US20070016256A1 US11/434,446 US43444606A US2007016256A1 US 20070016256 A1 US20070016256 A1 US 20070016256A1 US 43444606 A US43444606 A US 43444606A US 2007016256 A1 US2007016256 A1 US 2007016256A1
Authority
US
United States
Prior art keywords
obstruction
gland
force
regulated
meibomian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/434,446
Inventor
Donald Korb
Timothy Willis
Benjamin Gravely
Stephen Grenon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TearScience Inc
Original Assignee
Kolis Scientific Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/434,446 priority Critical patent/US20070016256A1/en
Application filed by Kolis Scientific Inc filed Critical Kolis Scientific Inc
Assigned to KOLIS SCIENTIFIC, INC. reassignment KOLIS SCIENTIFIC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRAVELY, BENJAMIN T., GRENON, STEPHEN M., KORB, DONALD R., WILLIS, TIMOTHY R.
Priority to US11/541,418 priority patent/US7981145B2/en
Publication of US20070016256A1 publication Critical patent/US20070016256A1/en
Priority to US11/928,681 priority patent/US8950405B2/en
Priority to US12/015,675 priority patent/US8128673B2/en
Priority to US12/015,558 priority patent/US7981146B2/en
Priority to US12/015,576 priority patent/US7981147B2/en
Priority to US12/015,721 priority patent/US8137390B2/en
Priority to US12/015,567 priority patent/US7976573B2/en
Priority to US12/015,600 priority patent/US9314369B2/en
Priority to US12/015,593 priority patent/US20080114423A1/en
Priority to US12/015,683 priority patent/US8128674B2/en
Priority to US12/015,584 priority patent/US8007524B2/en
Assigned to TEARSCIENCE, INC. reassignment TEARSCIENCE, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: KOLIS SCIENTIFIC, INC.
Priority to US13/025,951 priority patent/US8187310B2/en
Priority to US13/025,990 priority patent/US8187311B2/en
Priority to US13/183,901 priority patent/US9216028B2/en
Priority to US13/367,865 priority patent/US8523928B2/en
Priority to US13/367,908 priority patent/US8617229B2/en
Priority to US13/368,976 priority patent/US8632578B2/en
Priority to US14/510,843 priority patent/US20150025545A1/en
Priority to US14/510,863 priority patent/US10376273B2/en
Priority to US14/618,392 priority patent/US20150157347A1/en
Priority to US15/359,856 priority patent/US10952896B2/en
Priority to US16/358,754 priority patent/US20190282251A1/en
Priority to US17/208,465 priority patent/US20210205131A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/0625Warming the body, e.g. hyperthermia treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H7/00Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00772Apparatus for restoration of tear ducts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/02Radiation therapy using microwaves
    • A61N5/022Apparatus adapted for a specific treatment
    • A61N5/025Warming the body, e.g. hyperthermia treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B2018/044Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid
    • A61B2018/046Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid in liquid form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B2018/044Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid
    • A61B2018/048Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid in gaseous form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001Body part
    • A61F2007/0002Head or parts thereof
    • A61F2007/0004Eyes or part of the face surrounding the eyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H15/00Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains
    • A61H2015/0007Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains with balls or rollers rotating about their own axis
    • A61H2015/0014Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains with balls or rollers rotating about their own axis cylinder-like, i.e. rollers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0635Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643Applicators, probes irradiating specific body areas in close proximity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659Radiation therapy using light characterised by the wavelength of light used infrared
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/067Radiation therapy using light using laser light
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy

Definitions

  • This invention relates generally to the field of treatment of glands in order to restore natural secretory function to obstructed glands within the body and specifically, the meibomian glands of the eye.
  • the human body contains a number of glands including the lacrimal and meibomian glands of the eye, the sebaceous or pilo-sebaceous hair glands on the face and underarms, and the mammary glands in the breasts. These glands may malfunction due to age, irritation, environmental conditions, cellular debris, inflammation, hormonal imbalance and other causes. One common malfunction is the restriction or stoppage of the natural flow of secretions out of the gland.
  • the present invention provides methods and modalities to enhance and/or restore the natural flow of secretions out of the glands.
  • the tear film covering the ocular surfaces is composed of three layers.
  • the innermost layer in contact with the ocular surface is the mucus layer.
  • the middle layer comprising the bulk of the tear film is the aqueous layer, and the outermost layer is a thin (less than 250 nm) layer comprised of many lipids known as “meibum” or “sebum”.
  • the sebum is secreted by the meibomian glands, enlarged specialized sebaceous-type glands (hence, the use of “sebum” to describe the secretion) located on both the upper and lower eye lids, with orifices designed to discharge the lipid secretions onto the lid margins, thus forming the lipid layer of the tear film.
  • the typical upper lid has approximately 25 meibomian glands and the lower lid has approximately 20 meibomian glands, which are somewhat larger than those located in the upper lid.
  • the meibomian gland comprises various sac-like acini which discharge the secretion into the duct of the gland.
  • the secretion then passes into the orifices which are surrounded by smooth muscle tissue and the muscle of Riolan which are presumed to aid in the expression of sebum.
  • the meibomian gland orifices open on the lid margin usually along the mucocutaneous junction also known as the gray line.
  • the meibomian gland orifices are assumed to open with blinking and release minute amounts of sebum secretions onto the lid margin and then into the inferior tear meniscus.
  • the lipid “sebum” in the tear meniscus is spread upward and over the tear film of the open eye by the upward blink action. If the lipid secretions are optimal, and adequate lipid layer is maintained at the air interface to minimize evaporation and prevent dry eye states.
  • lipid secretions are inadequate the lipid layer is not adequate to minimize evaporation with resulting rapid evaporation leading to dry eye states.
  • a defective lipid layer or an incorrect quantity or quality of such lipids can result in accelerated evaporation of the aqueous layer which, in turn, causes symptoms which may include symptoms such as dryness, scratching, irritation, burning, tearing, redness, and itchiness, which are collectively be referred to as “dry eye” symptoms.
  • Dry eye states have many etiologies.
  • a common cause of common dry eye states is the condition known as “meibomian gland dysfunction”, a disorder where the glands are obstructed or occluded.
  • the terms “occluded” and “obstruction” as they relate to meibomian gland dysfunction are defined as partially or completely blocked or plugged meibomian glands. If completely obstructed the gland cannot secrete. If partially or intermittently occluded the gland may secrete either normal or decreased amounts of sebum. More usually the secretions are altered having semi-solid, thickened, congested secretions, frequently described as inspissated. The secretions may be clear or yellowish, the latter indicating possible infection.
  • meibomitis an inflammation of the meibomian glands leading to their dysfunction, is usually accompanied by blepharitis (inflammation of the lids). Meibomian gland dysfunction may accompany meibomitis, or meibomian gland dysfunction may be present without obvious lid inflammation. Meibomian gland dysfunction is frequently the result of keratotic obstruction of the individual meibomian gland orifices and/or the central duct (canal) of the gland which compromises the secretory functions of the individual meibomian glands.
  • these keratotic obstructions include a combination of desquamated epitlelial cells, keratin, sebaceous ground substance, and bacteria, see, Korb et al., Meibomian Gland Dysfunction and Contact Lens Intolerance, Journal of the Optometric Association, Vol. 51, Number 3, (1980), pp. 243-251. While meibomitis is obvious by inspection of the external lids, meibomian gland dysfunction may not be obvious even when examined with the magnification of the slit-lamp biomicroscope, since there may not be external signs or the external signs may be so minimal that they are overlooked.
  • the external signs of meibomian gland dysfunction may be limited to subtle alterations of the meibomian gland orifices, subtle or pronounced overgrowth of epithelium over the orifices, and pouting of the orifices of the glands with congealed material acting as the obstructive material under the epithelia overgrowth resulting in the pouting of the orifices.
  • Hormonal changes include those which occur during menopause, and particularly changing estrogen levels, can result in thickening of the oils secreted by the meibomian glands which results in clogged gland orifices. Further, decreased estrogen levels may also enhance conditions under which staphylococcal bacteria can proliferate. This can cause migration of the bacteria into the glands, thus resulting in a decreased secretion rate.
  • meibomian gland dysfunction Additional factors which may cause or exacerbate meibomian gland dysfunction include, age, contact lens wear and hygiene, disorders of blinking, extended computer use, cosmetic use, or other illness, particularly diabetes.
  • Clinical evaluation of the meibomian glands requires the application of pressure to the external surface of the eyelids over the meibomian glands in order to determine whether secretion is obtained from the individual gland with gentle pressure. If gentle pressure does not provide secretion, forceful expression may be utilized to determine if secretion can be obtained.
  • the state of an individual meibomian gland can vary from optimal, where clear meibomian sebum is expressed with gentle pressure; to mild or moderate meibomian gland dysfunction where milky fluid or inspissated or creamy secretion may be obtained; to total blockage where no secretion of any sort can be obtained even with the application of extreme pressure (see Korb, et al., “Increase in Tear Film Lipid Layer Thickness Following Treatment of Meibomian Gland Dysfunction”, Lacrimal Gland, tear Film, ad Dry Eye Syndromes, pp. 293-298, Edited by D. A. Sullivan, Plenum Press, New York (1994)).
  • Significant chemical changes of the meibomian gland secretions occur with meibomian gland dysfunction and consequently, the composition of the naturally occurring tear film is altered, which in turn, contributes to ocular disease which is generally known as “dye eye”.
  • the tear film operates as a singular entity and all of the layers thereof are important
  • the lipid layer which is secreted from the meibomian glands is of particular significance as it functions to slow the evaporation of the underlying layers and to lubricate the eyelid during blinking which prevents dry eye.
  • Eye drops such as Refresh®, Soothe® and Systane® are designed to closely replicate the naturally occurring healthy tear film. However, their use and administration is merely a treatment of symptoms and not of the underlying cause. Further, the use of drops is generally for an indefinite length of time and consequently, extended use can become burdensome and costly.
  • Pharmaceutical modalities such as the use of tetracycline have also been suggested to treat meibomian gland dysfunction and one such treatment is disclosed in United States Patent Publication no. US2003/011426 titled “Method for Treating Meibomian Gland Disease”, U.S. Pat. No. 6,455,583 titled “Method for Treating Meibomian Gland Disease” to Pflugfelder et al.
  • Each patch employed 19 light emitting diodes, emitting near infrared radiation from 850 nm to 1050 nm, with a peak at 940 nm.
  • the device produced 10 mW/cm 2 of energy operating on electrical power. Goto, E., et al,. Treatment of Non-Inflamed Obstructive Meibomian Gland dysfunction by an Infrared Warm Compression Device, British Journal of Ophthalmology, Vol. 86 (2002), pp. 1403-1407.
  • United States Patent Publication US2004/0237969 titled “Therapeutic Eye and Eye Lid Cover” comprises a pair of goggles that are adapted to deliver humid saturated air around the eyelids. This modality is also discussed in greater detail in the article titled “Tear Film Lipid Layer Thickness and Ocular Comfort after Meibomian Therapy via Latent Heat with a Novel Device in Normal Subjects by Mitra et al, published in Eye, (2004) at pages 1-4.
  • Another object of the present invention is to provide a meibomian gland treatment device that is a single step treatment, thus, eliminating the need for manual expression.
  • Yet another object of the present invention is to provide a meibomian gland treatment device which treats meibomian gland disease and not merely its symptoms.
  • Still another object of the present invention is to provide a meibomian gland treatment device that restores the natural sebum flow rather than merely attempting to replace or replicate the naturally occurring tear components.
  • a still further object of the present invention is to provide a meibomian gland treatment device which minimizes the chance of infection.
  • a still further object of the present invention is to provide a meibomian gland treatment device that is simple, inexpensive, and easy to use by the health care provider and the patient.
  • a method and apparatus for treating meibomian gland dysfunction wherein the flow of naturally occurring secretions from the meibomian gland is restored.
  • the method comprises applying a regulated force, regulated energy, regulated heat and/or chemical/pharmacological agent or combinations thereof to the eyelid to remove obstruction in order to restore the natural flow of secretion from the meibomian gland.
  • the obstruction may be dissolved, extracted and/or loosened from the gland wall, softened prior to extraction and/or expansion of the gland orifice or channel such that the normal secretions from the gland are restored.
  • the obstruction may be loosened from the gland wall or softened prior to extraction.
  • the force applied to loosen the obstruction may be of a pre-selected magnitude and applied for a pre-selected period of time.
  • the apparatus comprises means for applying an external or internal force, energy or heat (or a combination of the foregoing) to the gland to loosen the obstruction. Further aspects of the invention include providing means for softening, breaking up, and/or liquefying the obstruction prior to extraction and means for extracting the obstruction.
  • FIG. 1 is a schematic cut away view of the upper and lower eyelids illustrating the meibomian glands in cross section.
  • FIG. 2 is a cross sectional view of a single meibomian gland.
  • FIG. 3 a is a perspective view of a system for clearing obstructed meibomian glands.
  • FIG. 3 b is a broken away side view of the probe tip employed in the embodiment of FIG. 3 a.
  • FIG. 4 a is a perspective view of a second embodiment of the probe tip according to the present invention.
  • FIG. 4 b is a broken away side view of the probe tip of FIG. 4 a.
  • FIG. 4 c is a broken away side view of the probe tip of FIGS. 3 a and 4 a in place on an eye lid.
  • FIG. 5 is broken away side view of an alternate for clearing obstructed meibomian glands according to the present invention.
  • FIG. 6 a is a side view of an alternate embodiment of the probe tip having rollers for clearing obstructed meibomian glands according to the present invention.
  • FIG. 6 b is a side view of another alternate embodiment of the probe tip having rollers for clearing obstructed meibomian glands according to the present invention.
  • FIG. 7 is a side view of another alternate embodiment of the probe tip having rollers for clearing obstructed meibomian glands according to the present invention.
  • FIG. 8 is a perspective view of a suction device for clearing glands according to the present invention.
  • FIG. 9 is a side view of another embodiment of the apparatus for clearing meibomian glands according to the present invention.
  • FIG. 10 a is a schematic view of another embodiment of the apparatus for clearing meibomian glands according to the present invention.
  • FIG. 10 b is an exploded view of the hand-held probe of the embodiment of FIG. 10 a.
  • FIG. 10 c is a side view of the hand-held probe of FIGS. 10 a and 10 b applying force to an eyelid.
  • FIG. 11 a is a perspective.view of another embodiment of the meibomian gland treatment apparatus in the form of the hydro-oculator according to the present invention.
  • FIG. 11 b is a side view of the hydro-oculator of FIG. 11 a.
  • FIG. 11 c is a schematic side view of the hydro-oculator according to the present invention in place against the lower eyelid.
  • FIG. 11 d is a schematic side view of the hydro-oculator according to the present invention in place against the lower eyelid and showing the fluid filled bladder beginning to expand.
  • FIG. 11 e is a schematic side view of the hydro-oculator according to the present invention in place against the lower eyelid and showing the fluid filled bladder in a further expanded state.
  • each gland includes a channel C into which the secretion flows and an orifice O which opens on to the eyelid margin and through which the secretion must flow in order to be added to the tear film upon blinking. It will be seen that the glands are of different size, depending upon the location in the eyelid and that the orifice O is narrower than the channel C.
  • obstruction composition will vary with the etiology which produced it.
  • the obstruction will, in most cases, consist of a combination of, dead cells, keratin, bacteria, desquamated cells, sebaceous ground substance, milky fluid, inspissated or creamy secretions, or any combination of the foregoing in solid, semi-solid and thickened forms.
  • the obstruction may be in the gland channel, at the gland orifice, atop the gland orifice or a combination of the foregoing.
  • obstruction refers to any of the foregoing.
  • any obstruction of the channel will restrict or prevent secretions from exiting the gland and further, that in order to clear such obstructions or “occlusions”, the obstruction may be loosened from the gland wall, and/or broken up, fractured, softened, or liquified so that it will fit through the gland orifice without causing excessive pain. Lastly, the obstruction remnants must be expressed from the gland.
  • the present invention provides a method and apparatus to accomplish these tasks.
  • the obstruction P should be softened or liquefied prior to attempting extraction or expression.
  • the terms “softened” or “liqified” are intended to mean a “non-solid” flowable state.
  • softening or liquefying of the obstruction P should be effected as quickly as possible and regulated heat treatment time should be less than five (5) minutes with one to two (1-2) minutes being preferred without causing damage to the surrounding tissues of the ocular globe or the eye, such heat treatments can be electrical, laser heating, hot water conductive heating, infrared heating, ultrasonic. heating, RF heating, etc.
  • the means for applying the force may be selected from one or more of a number of modalities wherein the frequency of vibration may be including low frequency vibration (generally less than 1000 Hz), sonic (generally 1000 Hz to 20,000 Hz) or ultrasonic energy (generally greater than 20,000 Hz), fluid jet such as air or water, microwave energy, needles, laser energy, RF energy, aspiration/suction, vacuum, pressure, compression and functional equivalents thereof.
  • low frequency vibration generally less than 1000 Hz
  • sonic generally 1000 Hz to 20,000 Hz
  • ultrasonic energy generally greater than 20,000 Hz
  • fluid jet such as air or water, microwave energy, needles, laser energy, RF energy, aspiration/suction, vacuum, pressure, compression and functional equivalents thereof.
  • the physician will have to determine the optimum treatment parameters so that each of the foregoing modalities will be applied to the eyelid such that the force (or energy, as appropriate) provided thereby is transmitted through the eyelid tissue to the obstruction. Further, the treatment intensity and length of application of these external forces will vary with the size and composition of the obstruction.
  • the force can either be set per variable within a preselected range. Experiments were performed using an eccentric vibrating motor applied directly to the human eyelids. Bench tests of the vibration revealed the following data points, specifically setting number 3 was shown to be clinically effective to loosen the obstruction within the meibomian gland and orifice: Vibration Amplitude Setting Vibration Freq. (Hz.) (in/ ⁇ m) 1 51 .001 in. (25.4 ⁇ m) 2 118 .004 in. (100 ⁇ m) 3 165.5 .0062 in. (157.5 ⁇ m)
  • the obstruction may be operated upon such that it will pass through the orifice O in a manner which causes little or no pain or discomfort to the patent.
  • This can be accomplished by heating to soften or liquify the obstruction up to a range of thirty seven degrees centigrade (37° C.) to fifty degrees centigrade (50° C.) with the preferred operating range being forty degrees centigrade (40° C.) to forty seven degrees centigrade (47° C.) and desired modality of forty two degrees centigrade (42° C.) to forty six degrees centigrade (46° C.) so that it easily passes through the orifice (or with minimal non-painful expansion thereof).
  • Modalities for heating may include conduction, convection and radiation supplied by one or more of the following: thermal conduction, thermal convection, ultrasonic energy, laser energy, RF energy, direct and/or indirect transfer from heat source ad microwave energy which may be applied for a preselected period of time.
  • thermal conduction thermal convection
  • thermal convection ultrasonic energy
  • laser energy laser energy
  • RF energy direct and/or indirect transfer from heat source ad microwave energy which may be applied for a preselected period of time.
  • some of the foregoing modalities may also be employed to fracture or break up the obstruction.
  • a closed loop feedback control system well known to those skilled in the art (not shown) may be employed during heating to measure temperature proximate the eyelid to ensure that the obstruction does, in fact, reach a temperature sufficient to turn the obstructive material into a flowable, liquid or semi-liquid state.
  • Extraction of the softened, broken apart or fractured obstruction may be accomplished by one or more of the following: needles, micro-needles, aspiration/suction, vacuum, pressure and compression.
  • One embodiment of the invention is a suction system that is placed over the gland orifice may be employed to suck out the components of the softened, loosened or liquefied obstruction or the pieces thereof, as appropriate or alternatively, to employ suction to collect the obstruction as it exits the gland orifice.
  • the foregoing modalities for extracting or expressing the obstruction should be administered in a fashion that is regulated, i.e., done in a repeatable manner.
  • FIG. 3 a An apparatus for unplugging the obstructed gland channel C is schematically illustrated in FIG. 3 a .
  • the apparatus comprises a power source 100 which may be direct current (battery powered) or alternating current (wall socket) as desired.
  • the power source 100 is connected to a controller, generally indicated at 200 , which includes a power on/power off switch 210 .
  • the controller 200 includes a means 220 for applying an external force to the gland to loosen the obstruction.
  • the means 220 includes a probe 230 , which is adapted to vibrate at a preselected frequency at preselected amplitude.
  • the probe 230 may vibrate at sonic or ultrasonic frequencies as needed.
  • the means 220 for applying the regulated external force or regulated energy to the obstruction may also include fluid jet, air fluid, water fluid, microwave energy, needles, micro-needles, laser energy, RF energy, aspiration, suction, vacuum, pressure, piezoelectric, and compression.
  • FIG. 3B a small ultrasonic probe 230 (and specifically the probe tip) is illustrated in FIG. 4C in place on the eyelid.
  • the probe 230 is adapted to deliver ultrasonic vibrational energy through the skin into the obstruction P in order to loosen, liquefy, and/or fracture the obstruction. More specifically, by tuning the probe output so that the obstruction P resonates (by adjusting the frequency and amplitude of the signal) energy is efficiently transferred to the obstruction and sympathetic vibration of the obstruction P occurs with minimal energy transfer to the surrounding tissues. In some instances, vibration alone may be sufficient to change the characteristics of the obstruction P such that vigorous blinking may express the obstruction remnants.
  • the probe may be further equipped with aspiration means 260 (best illustrated in FIG. 4C for introducing aspiration, suction or vacuum into the gland channel C to evacuate the obstruction remnants.
  • aspiration means 260 best illustrated in FIG. 4C for introducing aspiration, suction or vacuum into the gland channel C to evacuate the obstruction remnants.
  • heat and aspiration may be employed in lieu of or in addition vibration.
  • the probe 230 may be equipped with a means for heating 270 such as a solid state heating element which may be regulated to provide relatively precise amounts of energy in the previously mentioned ranges that assists in softening, liquifying or melting the obstruction P via heat transfer through the tissue when the probe is placed against the tissue.
  • a means for heating 270 such as a solid state heating element which may be regulated to provide relatively precise amounts of energy in the previously mentioned ranges that assists in softening, liquifying or melting the obstruction P via heat transfer through the tissue when the probe is placed against the tissue.
  • a second embodiment of the invention employs microdermabraision or exfoliation to remove any cells or cellular material that may have overgrown the gland opening.
  • Microdermabraision is a process that was developed for use in dermatology to remove dead skin cells.
  • a probe or tip 330 is equipped with an abrasive surface 310 that is adapted to scrape the skin.
  • the abrasive employed is usually a diamond power or other suitable material, well known to those skilled in the art.
  • An inner tube 320 having a central bore 325 includes holes defining openings 330 through which a fluid such as air is pumped.
  • An outer covering 335 surrounds the tube 320 , but at its lower edge extends slightly lower and is spaced from the abrasive surface 310 and a space is defined between the lower ends of the respective tubes 320 , 335 .
  • the outer covering is connected to aspiration, vacuum, and/or suction that operates as described herein below.
  • the clinician would place the abrasive tip 310 in contact over the gland orifice creating a seal between the tip and the skin. Movement of the probe 330 would cause the abrasive 310 on the bottom of the tip to separate the cells from the skin and the aspiration, suction or vacuum would extract the cellular material from the vicinity of the gland opening. In addition, depending upon the obstruction, aspiration, suction and/or vacuum alone may be sufficient to extract the obstruction.
  • microdermabraision tip such as a heating element 340 which could be placed in the outer covering 335 near the tip.
  • the inner tube 320 could be equipped such that ultrasonic energy could be delivered to the obstruction as discussed herein above.
  • Another embodiment of the invention may employ a chemical agent to clean the gland margin and to remove or exfoliate cells from the meibomian gland orifice.
  • a chemical agent to clean the gland margin and to remove or exfoliate cells from the meibomian gland orifice.
  • Ophthaine® or a similar pharmacological agent may be employed to assist in removing epithelial cells from over the gland orifice.
  • a probe similar to that shown in FIG. 5 may be employed, except that the inner tube will deliver the chemical agent and the suction applied by the outer covering will be used to evacuate the used chemical agent and cellular material mixture away from the gland margin.
  • the heating and vibrational features discussed above may also be included.
  • a further embodiment of the invention may deliver vibrational and/or thermal energy to the obstruction P without contacting the gland.
  • One potential energy source is laser light supplied by titanium, argon, krypton or microwave energy. Extraction of the obstruction would be accomplished by the means described herein above.
  • a third embodiment of the invention employs pressure applied to the tissue as shown in FIGS. 6 a , 6 b and 7 by rollers (or drums) 375 which are placed in front of and/or behind the meibomian gland with the rollers applying constant regulated pressure to the meibomian glands to apply a “milking” type force to expel the obstruction to return the gland to normal secretion levels.
  • the rollers can be connected to heat, aspiration, vacuum, and/or suction that operate as described herein.
  • the physician would place the rollers 375 in contact with the eyelid, either inside, outside or both. Lateral movement of the rollers 375 would cause pressure to be applied to the gland to remove the obstruction.
  • aspiration, suction and/or vacuum could be applied to extract the obstruction and material from the vicinity of the gland opening.
  • suction and/or vacuum alone may be sufficient to extract the obstruction.
  • rollers such as a regulated heating element (not shown) which could be placed in the outer covering near the tip as shown in FIG. 6A .
  • the roller 375 could be equipped such that ultrasonic energy could be delivered to the obstruction as discussed herein above.
  • FIG. 8 illustrates a prototype hand held suction system generally indicated at 400 that was constructed.
  • the system comprised an AC power supply 410 which powered a suction pump 420 to which tubing 430 was connected.
  • a probe 440 was connected at the opposite end of tubing 430 .
  • a tip 450 having a 1 mm diameter and a 200 micron orifice was attached to the end of the probe 440 .
  • the probe end 460 was curved for ergonomic access to the gland orifice.
  • the tip 450 is placed on or proximate the gland orifice and the applied vacuum is used to collect the obstruction as it exits the orifice or may alternatively be employed to assist in expression of the obstruction.
  • FIG. 9 illustrates another prototype of a hand held apparatus generally indicated at 500 that was constructed.
  • the system comprised a power supply 510 which powered an electromagnet (not shown) which was encased in a handle 530 that may be easily held by the clinician in one hand.
  • a rod 540 is mounted for reciprocating motion to the output of the electromagnet. The throw or amount of movement of the rod 540 is 0.5 mm.
  • a back plate 550 which is substantially perpendicular to the axis of rod 540 .
  • a lever 560 is pivotally mounted to rod 540 and operates to actuate a roller 570 .
  • a heating means or heater 580 was mounted in backplate 550 .
  • the heater 580 was also provided with an appropriate power source.
  • the device is positioned such that the back plate 550 is positioned between the cornea and the back surface of the eye lid.
  • the lever 560 is actuated such that the roller 570 comes into contact with the front surface of the eye lid.
  • the arc of the roller is such that the eye lid is squeezed between the foregoing
  • the clinician may elect to maintain the back plate and the roller under tension for a preselected period of time to soften the obstruction.
  • further pressure on the lever 560 will cause the roller to move from the bottom of the meibomian gland (the end away from the orifice) to the top of the gland to express the obstruction from the gland in am “milking type” motion.
  • a repeatable regulated method for opening obstructed meibomian glands is provided.
  • the embodiment illustrated in FIGS. 10A through 10C the present invention prototype is a hand held apparatus generally indicated at 600.
  • the apparatus comprises a power source 610 which may be a DC source such as a battery or an AC source similar to those discussed herein above.
  • the power source 610 resides within a housing 620 .
  • the power source 610 provides electrical current to a wave form generator 625 which powers an acoustic amplifier 630 (for example, a small audio speaker) also located within housing 620 and mounted at an ergonomic angle therein.
  • the acoustic amplifier 630 is programmed to vibrate in a wave format at a frequency of 0 to 200 Hz at an amplitude in the range of 0.25 mm to 5 mm.
  • acoustic amplifier 630 Mounted in operative association atop the acoustic amplifier 630 is an annulus 635 that floats thereon and includes a cone shaped housing 640 extending perpendicularly away from the amplifier 625 that encloses the amplifier 625
  • the end of the housing 640 is adapted to mount a variety of tips 650 .
  • the tip may comprise a roller 655 mounted for rotation in a cradle 665 .
  • the tip 650 may be modified to include a regulated heating element (not shown) that acts to soften the obstruction.
  • Other tip configurations may include a vacuum for collecting the obstruction after expression thereof from the gland and different tip configurations to apply various contact areas and resulting forces.
  • the first force may be a fixed constantly applied force or one that increases to a preselected maximum.
  • FIGS. 11A through 11E Another embodiment of the invention is shown in FIGS. 11A through 11E wherein the treatment apparatus is incorporated into a goggle-like device, termed herein as the “hydro-oculator” which is a head borne device that locates the treatment mechanism proximate the eyelids, generally indicated at 700 .
  • the hydro-oculator 700 comprises a flexible frame 705 having a headband 710 (which may be elastic) connected thereto at each end.
  • a molded housing 720 Connected to the bottom of the frame 705 is a molded housing 720 which has an angled leg 725 which is adapted to overlie the cheek bone when the apparatus is in use.
  • an expandable fluid or gas impermeable container referred to herein as a bladder 730 is positioned within the cavity defined by the space between the housing and the lower eye lid.
  • a pumping mechanism is provided that facilitates movement of a fluid or gas, collectively referred to herein as a “medium” (not shown) into and out of each of the respective bladders 730 .
  • the patient would position the hydo-oclulator 700 on his or her head such that the leg 725 of molded housing 730 rests on the upper cheek bone as best shown in FIGS. 11C through 11E .
  • the regulated heated medium is pumped into the bladders 730 causing partial expansion thereof in order to apply a pressure to the eyelids in the range of from zero to fifty pounds per square inch (50 psi).
  • the bladder containing the heated medium (a water based solution being preferred) is positioned on the eyelids over the meibomian glands for a preselected period of time (up to thirty minutes) to soften the obstruction. It is desirable to place the heat source in direct contact with the eyelids which thereby transmits thermal energy to the meibomian glands, in contrast to the prior art which heats a confined space in front of the open eye where heat could be transmitted to the ocular bulbi structures such as the crystalline lens which introduces the possibility of cataract formation.
  • the bladder is slowly expanded to a preselected maximum such that the force on the gland increases from the bottom up to the top or orifice end of the gland such that the obstruction is expressed therefrom in a “milking” type of action.
  • Milking may be applied at a preselected frequency between zero and five hertz (0-5 Hz) and for a preselected period of time, usually not more than thirty minutes.
  • the medium may be “pulsed”, i.e., milkingly moved into and out of the bladder to further facilitate expression of the obstruction from the gland. Pulsing may also be achieved by providing an external force to the bladder and transmitting the force through the fluid into the gland.
  • Pulsing may be applied at a preselected frequency between zero and one hundred hertz (0-100 Hz) for a preselected period time, usually not more than thirty (30) minutes.
  • a chemical or pharmacological agent may be inserted into the meibomian gland to assist in softening the obstruction and any of the extraction modalities mentioned above may be further employed to assist in removing the obstruction.
  • Another embodiment of the invention may employ a chemical agent or compound to clean the glandular margin to remove or exfoliate cells from the gland orifice.
  • a probe similar to that shown in FIG. 5 may be employed, except that the outer drum or roller will deliver the chemical agent and the suction applied by the outer covering will be used to evacuate the used chemical agent and cellular material mixture away from the gland margin.
  • the heating and vibrational features discussed above may also be included.
  • a further embodiment of the invention may deliver vibrational and/or thermal energy to the obstruction P without contacting the gland.
  • One potential energy source is laser light supplied by a titanium-sapphire, argon, krypton, RF energy or microwave energy. Extraction of the obstruction would be accomplished by the means described herein above.
  • Another embodiment of the invention employs the use of chemical or pharmacological agents to open or dilate the gland and gland orifice wherein the obstruction naturally is expressed and returns the normal secretions of the gland.
  • the chemical or pharmaceutical agent would be used to soften or breakup the obstruction with such obstruction being expressed with the use of devices as defined above or combinations thereof.
  • Chemical or pharmacological agents may also be used in connection with the device for post treatment. Once the glands have been opened then chemical or pharmacological agents may be used to enhance the normal production or secretion to maintain the glands in its unblocked state.
  • Dilation of the meibomian gland channel and orifice may also be employed to loosen or free the obstruction from the gland walls. Dilation may be accomplished by chemical, pharmacological, or mechanical means.
  • Stimulation of the meibomian gland may also be employed in conjunction with the other modalities discussed above to loosen or fracture the obstruction.

Abstract

A method and apparatus for treating gland dysfunction caused by gland obstruction in order to restore the natural flow of secretion from the gland comprises the application of a combination of energy, suction, vibration, heat, aspiration, chemical agents and pharmacological agents to loosen and thereafter remove the obstructive material.

Description

    PRIORITY CLAIM
  • This invention claims priority from U.S. Provisional Patent Application Ser. No. 60/700,233 filed Jul. 18, 2005, which is incorporated herein by reference in its entirety and is hereby made a part of this specification.
  • FIELD OF THE INVENTION
  • This invention relates generally to the field of treatment of glands in order to restore natural secretory function to obstructed glands within the body and specifically, the meibomian glands of the eye.
  • BACKGROUND OF THE INVENTION
  • The human body contains a number of glands including the lacrimal and meibomian glands of the eye, the sebaceous or pilo-sebaceous hair glands on the face and underarms, and the mammary glands in the breasts. These glands may malfunction due to age, irritation, environmental conditions, cellular debris, inflammation, hormonal imbalance and other causes. One common malfunction is the restriction or stoppage of the natural flow of secretions out of the gland. The present invention provides methods and modalities to enhance and/or restore the natural flow of secretions out of the glands.
  • While the description that follows is directed to the meibomian glands of the eye, it will be understood that the present invention may be employed to treat all of the external glands of the body. With particular reference to the human eye, the tear film covering the ocular surfaces is composed of three layers. The innermost layer in contact with the ocular surface is the mucus layer. The middle layer comprising the bulk of the tear film is the aqueous layer, and the outermost layer is a thin (less than 250 nm) layer comprised of many lipids known as “meibum” or “sebum”. The sebum is secreted by the meibomian glands, enlarged specialized sebaceous-type glands (hence, the use of “sebum” to describe the secretion) located on both the upper and lower eye lids, with orifices designed to discharge the lipid secretions onto the lid margins, thus forming the lipid layer of the tear film. The typical upper lid has approximately 25 meibomian glands and the lower lid has approximately 20 meibomian glands, which are somewhat larger than those located in the upper lid. The meibomian gland comprises various sac-like acini which discharge the secretion into the duct of the gland. The secretion then passes into the orifices which are surrounded by smooth muscle tissue and the muscle of Riolan which are presumed to aid in the expression of sebum. The meibomian gland orifices open on the lid margin usually along the mucocutaneous junction also known as the gray line. The meibomian gland orifices are assumed to open with blinking and release minute amounts of sebum secretions onto the lid margin and then into the inferior tear meniscus. The lipid “sebum” in the tear meniscus is spread upward and over the tear film of the open eye by the upward blink action. If the lipid secretions are optimal, and adequate lipid layer is maintained at the air interface to minimize evaporation and prevent dry eye states. If the lipid secretions are inadequate the lipid layer is not adequate to minimize evaporation with resulting rapid evaporation leading to dry eye states. Thus, it will be seen that a defective lipid layer or an incorrect quantity or quality of such lipids can result in accelerated evaporation of the aqueous layer which, in turn, causes symptoms which may include symptoms such as dryness, scratching, irritation, burning, tearing, redness, and itchiness, which are collectively be referred to as “dry eye” symptoms.
  • Dry eye states have many etiologies. A common cause of common dry eye states is the condition known as “meibomian gland dysfunction”, a disorder where the glands are obstructed or occluded. As employed herein the terms “occluded” and “obstruction” as they relate to meibomian gland dysfunction are defined as partially or completely blocked or plugged meibomian glands. If completely obstructed the gland cannot secrete. If partially or intermittently occluded the gland may secrete either normal or decreased amounts of sebum. More usually the secretions are altered having semi-solid, thickened, congested secretions, frequently described as inspissated. The secretions may be clear or yellowish, the latter indicating possible infection. meibomitis, an inflammation of the meibomian glands leading to their dysfunction, is usually accompanied by blepharitis (inflammation of the lids). Meibomian gland dysfunction may accompany meibomitis, or meibomian gland dysfunction may be present without obvious lid inflammation. Meibomian gland dysfunction is frequently the result of keratotic obstruction of the individual meibomian gland orifices and/or the central duct (canal) of the gland which compromises the secretory functions of the individual meibomian glands. More particularly, these keratotic obstructions include a combination of desquamated epitlelial cells, keratin, sebaceous ground substance, and bacteria, see, Korb et al., Meibomian Gland Dysfunction and Contact Lens Intolerance, Journal of the Optometric Association, Vol. 51, Number 3, (1980), pp. 243-251. While meibomitis is obvious by inspection of the external lids, meibomian gland dysfunction may not be obvious even when examined with the magnification of the slit-lamp biomicroscope, since there may not be external signs or the external signs may be so minimal that they are overlooked. The external signs of meibomian gland dysfunction may be limited to subtle alterations of the meibomian gland orifices, subtle or pronounced overgrowth of epithelium over the orifices, and pouting of the orifices of the glands with congealed material acting as the obstructive material under the epithelia overgrowth resulting in the pouting of the orifices.
  • Hormonal changes include those which occur during menopause, and particularly changing estrogen levels, can result in thickening of the oils secreted by the meibomian glands which results in clogged gland orifices. Further, decreased estrogen levels may also enhance conditions under which staphylococcal bacteria can proliferate. This can cause migration of the bacteria into the glands, thus resulting in a decreased secretion rate.
  • When the flow of secretions from the meibomian gland is restricted due to the existence of an obstruction, epithelial cells on the eyelid margin tend to grow over the gland orifice thus further restricting sebum flow and exacerbating the dry eye condition.
  • Additional factors which may cause or exacerbate meibomian gland dysfunction include, age, contact lens wear and hygiene, disorders of blinking, extended computer use, cosmetic use, or other illness, particularly diabetes.
  • Clinical evaluation of the meibomian glands requires the application of pressure to the external surface of the eyelids over the meibomian glands in order to determine whether secretion is obtained from the individual gland with gentle pressure. If gentle pressure does not provide secretion, forceful expression may be utilized to determine if secretion can be obtained. Thus, the state of an individual meibomian gland can vary from optimal, where clear meibomian sebum is expressed with gentle pressure; to mild or moderate meibomian gland dysfunction where milky fluid or inspissated or creamy secretion may be obtained; to total blockage where no secretion of any sort can be obtained even with the application of extreme pressure (see Korb, et al., “Increase in Tear Film Lipid Layer Thickness Following Treatment of Meibomian Gland Dysfunction”, Lacrimal Gland, tear Film, ad Dry Eye Syndromes, pp. 293-298, Edited by D. A. Sullivan, Plenum Press, New York (1994)). Significant chemical changes of the meibomian gland secretions occur with meibomian gland dysfunction and consequently, the composition of the naturally occurring tear film is altered, which in turn, contributes to ocular disease which is generally known as “dye eye”.
  • While the tear film operates as a singular entity and all of the layers thereof are important, the lipid layer, which is secreted from the meibomian glands is of particular significance as it functions to slow the evaporation of the underlying layers and to lubricate the eyelid during blinking which prevents dry eye.
  • In response to the foregoing, various treatment modalities have been developed in order to treat the dry eye condition, including drops which are intended to replicate and replace the natural tear film, pharmaceuticals which are intended to stimulate the gland and cells providing the components of the tear film and various warm compresses and warming devices which are designed to treat meibomitis and the meibomian glands.
  • Eye drops such as Refresh®, Soothe® and Systane® are designed to closely replicate the naturally occurring healthy tear film. However, their use and administration is merely a treatment of symptoms and not of the underlying cause. Further, the use of drops is generally for an indefinite length of time and consequently, extended use can become burdensome and costly. Pharmaceutical modalities such as the use of tetracycline have also been suggested to treat meibomian gland dysfunction and one such treatment is disclosed in United States Patent Publication no. US2003/011426 titled “Method for Treating Meibomian Gland Disease”, U.S. Pat. No. 6,455,583 titled “Method for Treating Meibomian Gland Disease” to Pflugfelder et al. and PCT Publication No. WO 99/58131 titled “Use of Tetracyclines for Treating Meibomian Gland Disease”. However, this treatment has not proven to be clinically effective for meibomian gland obstruction, and it may be unnecessary as much meibomian gland dysfunction is the result of an obstruction of the gland without infection. The use of corticosteroids have also been proposed to treat meibomian gland dysfunction as disclosed in U.S. Pat. No. 6,153,607 titled “Non-preserved Topical Corticosteroid for Treatment of Dry Eye, filamentary Keratitis, and Delayed Tear Clearance (or Turnover) to Pflugfelder et al. Again, this proposed treatment appears to treat the symptom of dry eye, as opposed to treatment of the underlying cause and further presents the risks of inducing cataracts and glaucoma. Additionally, the use of topically applied androgens or androgen analogues have also been used to treat acute dry eye signs and symptoms in Keratoconjuctivitis Sicca as disclosed in U.S. Pat. No. 5,958,912 and U.S. Pat. No. 6,107,289 both titled “Ocular Therapy in Keratoconjunctivitis Sicca Using Topically Applied Androgens of TGF-β” and both issued to Sullivan.
  • Another modality for the treatment of meibomian gland dysfunction is disclosed in European Patent Application Ser. No. PCT/GB2003/004782 titled “Eyelid Margin Wipes Comprising Chemical Means for Temperature Adjustment”. As disclosed in this patent application, an eyelid margin wipe is provided wherein prior to use, a chemical agent is activated that will heat the wipe to about 32° C. to about 55° C. and wherein the temperature will be maintained for at least ten minutes to treat the eyelid margin. This method is not without its drawbacks in that lid irritation can be exacerbated by non-specific heating and the heating range noted as comfortable at over 50° C. would burn the skin. Another method of heating the eyelids and meibomian glands uses near infrared radiation. More specifically, two hard eye patches were attached to an eye mask according to the pupillary distance of the subject. The eye mask was held in place by an elastic headband. Each patch employed 19 light emitting diodes, emitting near infrared radiation from 850 nm to 1050 nm, with a peak at 940 nm. The device produced 10 mW/cm2 of energy operating on electrical power. Goto, E., et al,. Treatment of Non-Inflamed Obstructive Meibomian Gland dysfunction by an Infrared Warm Compression Device, British Journal of Ophthalmology, Vol. 86 (2002), pp. 1403-1407.
  • United States Patent Publication US2004/0237969 titled “Therapeutic Eye and Eye Lid Cover” comprises a pair of goggles that are adapted to deliver humid saturated air around the eyelids. This modality is also discussed in greater detail in the article titled “Tear Film Lipid Layer Thickness and Ocular Comfort after Meibomian Therapy via Latent Heat with a Novel Device in Normal Subjects by Mitra et al, published in Eye, (2004) at pages 1-4.
  • United States Patent Publication US2003/0233135 titled “Method and Apparatus for Preventing and Treating Eyelid Problems” by Yee attempts to clear the plugged meibomian glands by means of electrical stimulation of the muscle of Riolan which the invention presumed to aid in the expression of the meibomian gland secretion.
  • It will be noted that all of the above-noted treatment modalities are not without their inherent drawbacks and deficiencies. For example, the current application of heat to the meibomian glands treatment is very time consuming. Normally, treatment consists of at least fifteen minutes of heat application which is followed by manual expression, which normally consists of placing a cotton swab or firm surface behind the portion of the eye lid where the blocked meibomian gland is located and manually squeezing the obstruction from the gland, the foregoing often being quite painful despite the use of topical anesthesia provided in eye drop form.
  • It is therefore an object of the present invention to provide a meibomian gland treatment that overcomes the drawbacks and deficiencies of the prior art.
  • Another object of the present invention is to provide a meibomian gland treatment device that is a single step treatment, thus, eliminating the need for manual expression.
  • Yet another object of the present invention is to provide a meibomian gland treatment device which treats meibomian gland disease and not merely its symptoms.
  • Still another object of the present invention is to provide a meibomian gland treatment device that restores the natural sebum flow rather than merely attempting to replace or replicate the naturally occurring tear components.
  • A still further object of the present invention is to provide a meibomian gland treatment device which minimizes the chance of infection.
  • A still further object of the present invention is to provide a meibomian gland treatment device that is simple, inexpensive, and easy to use by the health care provider and the patient.
  • SUMMARY OF THE INVENTION
  • According to the present invention there is provided a method and apparatus for treating meibomian gland dysfunction wherein the flow of naturally occurring secretions from the meibomian gland is restored. The method comprises applying a regulated force, regulated energy, regulated heat and/or chemical/pharmacological agent or combinations thereof to the eyelid to remove obstruction in order to restore the natural flow of secretion from the meibomian gland. In further aspects of the invention, the obstruction may be dissolved, extracted and/or loosened from the gland wall, softened prior to extraction and/or expansion of the gland orifice or channel such that the normal secretions from the gland are restored. In other aspects of the invention the obstruction may be loosened from the gland wall or softened prior to extraction. Additionally, the force applied to loosen the obstruction may be of a pre-selected magnitude and applied for a pre-selected period of time.
  • The apparatus comprises means for applying an external or internal force, energy or heat (or a combination of the foregoing) to the gland to loosen the obstruction. Further aspects of the invention include providing means for softening, breaking up, and/or liquefying the obstruction prior to extraction and means for extracting the obstruction.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic cut away view of the upper and lower eyelids illustrating the meibomian glands in cross section.
  • FIG. 2 is a cross sectional view of a single meibomian gland.
  • FIG. 3 a is a perspective view of a system for clearing obstructed meibomian glands.
  • FIG. 3 b is a broken away side view of the probe tip employed in the embodiment of FIG. 3 a.
  • FIG. 4 a is a perspective view of a second embodiment of the probe tip according to the present invention.
  • FIG. 4 b is a broken away side view of the probe tip of FIG. 4 a.
  • FIG. 4 c is a broken away side view of the probe tip of FIGS. 3 a and 4 a in place on an eye lid.
  • FIG. 5 is broken away side view of an alternate for clearing obstructed meibomian glands according to the present invention.
  • FIG. 6 a is a side view of an alternate embodiment of the probe tip having rollers for clearing obstructed meibomian glands according to the present invention.
  • FIG. 6 b is a side view of another alternate embodiment of the probe tip having rollers for clearing obstructed meibomian glands according to the present invention.
  • FIG. 7 is a side view of another alternate embodiment of the probe tip having rollers for clearing obstructed meibomian glands according to the present invention.
  • FIG. 8 is a perspective view of a suction device for clearing glands according to the present invention.
  • FIG. 9 is a side view of another embodiment of the apparatus for clearing meibomian glands according to the present invention.
  • FIG. 10 a is a schematic view of another embodiment of the apparatus for clearing meibomian glands according to the present invention.
  • FIG. 10 b is an exploded view of the hand-held probe of the embodiment of FIG. 10 a.
  • FIG. 10 c is a side view of the hand-held probe of FIGS. 10 a and 10 b applying force to an eyelid.
  • FIG. 11 a is a perspective.view of another embodiment of the meibomian gland treatment apparatus in the form of the hydro-oculator according to the present invention.
  • FIG. 11 b is a side view of the hydro-oculator of FIG. 11 a.
  • FIG. 11 c is a schematic side view of the hydro-oculator according to the present invention in place against the lower eyelid.
  • FIG. 11 d is a schematic side view of the hydro-oculator according to the present invention in place against the lower eyelid and showing the fluid filled bladder beginning to expand.
  • FIG. 11 e is a schematic side view of the hydro-oculator according to the present invention in place against the lower eyelid and showing the fluid filled bladder in a further expanded state.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • While the present invention will be described more fully hereinafter, it is to be understood at the outset that persons of skill in the art may modify the invention herein described while still achieving the favorable results of this invention. Accordingly, the description that follows is to be understood as a broad teaching disclosure directed to persons of skill in the appropriate arts, and not as limiting upon the present invention.
  • Referring now to FIG. 1, the location of the meibomian glands M are shown on the upper and lower eyelids. As briefly stated herein above, the upper lid contains approximately 25 meibomian glands and the lower lid contains approximately 20 meibomian glands. As shown in FIG. 2, each gland includes a channel C into which the secretion flows and an orifice O which opens on to the eyelid margin and through which the secretion must flow in order to be added to the tear film upon blinking. It will be seen that the glands are of different size, depending upon the location in the eyelid and that the orifice O is narrower than the channel C.
  • As briefly mentioned herein above, obstruction composition will vary with the etiology which produced it. However, the obstruction will, in most cases, consist of a combination of, dead cells, keratin, bacteria, desquamated cells, sebaceous ground substance, milky fluid, inspissated or creamy secretions, or any combination of the foregoing in solid, semi-solid and thickened forms. The obstruction may be in the gland channel, at the gland orifice, atop the gland orifice or a combination of the foregoing. As employed herein, obstruction refers to any of the foregoing.
  • Thus, it is self-evident that any obstruction of the channel will restrict or prevent secretions from exiting the gland and further, that in order to clear such obstructions or “occlusions”, the obstruction may be loosened from the gland wall, and/or broken up, fractured, softened, or liquified so that it will fit through the gland orifice without causing excessive pain. Lastly, the obstruction remnants must be expressed from the gland. The present invention provides a method and apparatus to accomplish these tasks.
  • According to the method of the present invention, the obstruction P should be softened or liquefied prior to attempting extraction or expression. With respect to the foregoing, the terms “softened” or “liqified” are intended to mean a “non-solid” flowable state. In addition, in order to be clinically satisfactory, softening or liquefying of the obstruction P should be effected as quickly as possible and regulated heat treatment time should be less than five (5) minutes with one to two (1-2) minutes being preferred without causing damage to the surrounding tissues of the ocular globe or the eye, such heat treatments can be electrical, laser heating, hot water conductive heating, infrared heating, ultrasonic. heating, RF heating, etc. This necessarily requires the addition of a greater amount of energy (heating) than is deliverable by the conventional application of hot compresses which according to current practice are applied for 3-15 minutes prior to the clinician attempting to remove the obstruction. Once the obstruction is softened or liquified, removal is obtained by the application of a regulated force to the gland. More specifically, it is contemplated by the present invention that the force applied be a repeatable controlled force, as more fully explained herein below.
  • Treatment to remove the obstruction will involve the application of an external regulated force to the eyelid and/or directly over the obstructed orifice to loosen the obstruction within the gland G and the orifice. The means for applying the force may be selected from one or more of a number of modalities wherein the frequency of vibration may be including low frequency vibration (generally less than 1000 Hz), sonic (generally 1000 Hz to 20,000 Hz) or ultrasonic energy (generally greater than 20,000 Hz), fluid jet such as air or water, microwave energy, needles, laser energy, RF energy, aspiration/suction, vacuum, pressure, compression and functional equivalents thereof. In addition, once a modality is chosen, the physician will have to determine the optimum treatment parameters so that each of the foregoing modalities will be applied to the eyelid such that the force (or energy, as appropriate) provided thereby is transmitted through the eyelid tissue to the obstruction. Further, the treatment intensity and length of application of these external forces will vary with the size and composition of the obstruction. Once a treatment protocol is established, the force can either be set per variable within a preselected range. Experiments were performed using an eccentric vibrating motor applied directly to the human eyelids. Bench tests of the vibration revealed the following data points, specifically setting number 3 was shown to be clinically effective to loosen the obstruction within the meibomian gland and orifice:
    Vibration Amplitude
    Setting Vibration Freq. (Hz.) (in/μm)
    1 51 .001 in. (25.4 μm)
    2 118 .004 in. (100 μm)
    3 165.5 .0062 in. (157.5 μm)
  • Once the obstruction has been loosened from the walls of the gland, it may be operated upon such that it will pass through the orifice O in a manner which causes little or no pain or discomfort to the patent. This can be accomplished by heating to soften or liquify the obstruction up to a range of thirty seven degrees centigrade (37° C.) to fifty degrees centigrade (50° C.) with the preferred operating range being forty degrees centigrade (40° C.) to forty seven degrees centigrade (47° C.) and desired modality of forty two degrees centigrade (42° C.) to forty six degrees centigrade (46° C.) so that it easily passes through the orifice (or with minimal non-painful expansion thereof). Modalities for heating may include conduction, convection and radiation supplied by one or more of the following: thermal conduction, thermal convection, ultrasonic energy, laser energy, RF energy, direct and/or indirect transfer from heat source ad microwave energy which may be applied for a preselected period of time. By varying the amplitude, intensity and length of application, some of the foregoing modalities may also be employed to fracture or break up the obstruction. It will be noted that a closed loop feedback control system, well known to those skilled in the art (not shown) may be employed during heating to measure temperature proximate the eyelid to ensure that the obstruction does, in fact, reach a temperature sufficient to turn the obstructive material into a flowable, liquid or semi-liquid state.
  • Extraction of the softened, broken apart or fractured obstruction may be accomplished by one or more of the following: needles, micro-needles, aspiration/suction, vacuum, pressure and compression. One embodiment of the invention is a suction system that is placed over the gland orifice may be employed to suck out the components of the softened, loosened or liquefied obstruction or the pieces thereof, as appropriate or alternatively, to employ suction to collect the obstruction as it exits the gland orifice. In order to be clinically effective, the foregoing modalities for extracting or expressing the obstruction should be administered in a fashion that is regulated, i.e., done in a repeatable manner.
  • An apparatus for unplugging the obstructed gland channel C is schematically illustrated in FIG. 3 a. The apparatus comprises a power source 100 which may be direct current (battery powered) or alternating current (wall socket) as desired. The power source 100 is connected to a controller, generally indicated at 200, which includes a power on/power off switch 210. The controller 200 includes a means 220 for applying an external force to the gland to loosen the obstruction. The means 220 includes a probe 230, which is adapted to vibrate at a preselected frequency at preselected amplitude. The probe 230 may vibrate at sonic or ultrasonic frequencies as needed. In addition, means for varying the frequency 240 and amplitude 250 of the probe output, well known to those skilled in the art, are provided. The means 220 for applying the regulated external force or regulated energy to the obstruction may also include fluid jet, air fluid, water fluid, microwave energy, needles, micro-needles, laser energy, RF energy, aspiration, suction, vacuum, pressure, piezoelectric, and compression.
  • Turning now to FIG. 3B, a small ultrasonic probe 230 (and specifically the probe tip) is illustrated in FIG. 4C in place on the eyelid. The probe 230 is adapted to deliver ultrasonic vibrational energy through the skin into the obstruction P in order to loosen, liquefy, and/or fracture the obstruction. More specifically, by tuning the probe output so that the obstruction P resonates (by adjusting the frequency and amplitude of the signal) energy is efficiently transferred to the obstruction and sympathetic vibration of the obstruction P occurs with minimal energy transfer to the surrounding tissues. In some instances, vibration alone may be sufficient to change the characteristics of the obstruction P such that vigorous blinking may express the obstruction remnants.
  • In addition to vibration alternative force, energy, aspiration and/or chemical/pharmacological agents can be used to open up the channel C. The probe may be further equipped with aspiration means 260 (best illustrated in FIG. 4C for introducing aspiration, suction or vacuum into the gland channel C to evacuate the obstruction remnants. Alternatively, heat and aspiration may be employed in lieu of or in addition vibration.
  • In another aspect of the invention, the probe 230 may be equipped with a means for heating 270 such as a solid state heating element which may be regulated to provide relatively precise amounts of energy in the previously mentioned ranges that assists in softening, liquifying or melting the obstruction P via heat transfer through the tissue when the probe is placed against the tissue.
  • A second embodiment of the invention (FIG. 5) employs microdermabraision or exfoliation to remove any cells or cellular material that may have overgrown the gland opening. Microdermabraision is a process that was developed for use in dermatology to remove dead skin cells. As shown in FIG. 5 a probe or tip 330 is equipped with an abrasive surface 310 that is adapted to scrape the skin. The abrasive employed is usually a diamond power or other suitable material, well known to those skilled in the art. An inner tube 320 having a central bore 325 includes holes defining openings 330 through which a fluid such as air is pumped. An outer covering 335 surrounds the tube 320, but at its lower edge extends slightly lower and is spaced from the abrasive surface 310 and a space is defined between the lower ends of the respective tubes 320, 335. The outer covering is connected to aspiration, vacuum, and/or suction that operates as described herein below.
  • In operation, the clinician would place the abrasive tip 310 in contact over the gland orifice creating a seal between the tip and the skin. Movement of the probe 330 would cause the abrasive 310 on the bottom of the tip to separate the cells from the skin and the aspiration, suction or vacuum would extract the cellular material from the vicinity of the gland opening. In addition, depending upon the obstruction, aspiration, suction and/or vacuum alone may be sufficient to extract the obstruction.
  • Additional features may also be providing to the microdermabraision tip such as a heating element 340 which could be placed in the outer covering 335 near the tip. In addition, the inner tube 320 could be equipped such that ultrasonic energy could be delivered to the obstruction as discussed herein above.
  • Another embodiment of the invention may employ a chemical agent to clean the gland margin and to remove or exfoliate cells from the meibomian gland orifice. For example Ophthaine® or a similar pharmacological agent may be employed to assist in removing epithelial cells from over the gland orifice. A probe similar to that shown in FIG. 5 may be employed, except that the inner tube will deliver the chemical agent and the suction applied by the outer covering will be used to evacuate the used chemical agent and cellular material mixture away from the gland margin. Similarly, the heating and vibrational features discussed above may also be included.
  • A further embodiment of the invention may deliver vibrational and/or thermal energy to the obstruction P without contacting the gland. One potential energy source is laser light supplied by titanium, argon, krypton or microwave energy. Extraction of the obstruction would be accomplished by the means described herein above.
  • A third embodiment of the invention employs pressure applied to the tissue as shown in FIGS. 6 a, 6 b and 7 by rollers (or drums) 375 which are placed in front of and/or behind the meibomian gland with the rollers applying constant regulated pressure to the meibomian glands to apply a “milking” type force to expel the obstruction to return the gland to normal secretion levels. The rollers can be connected to heat, aspiration, vacuum, and/or suction that operate as described herein.
  • In operation, the physician would place the rollers 375 in contact with the eyelid, either inside, outside or both. Lateral movement of the rollers 375 would cause pressure to be applied to the gland to remove the obstruction. Alternatively, aspiration, suction and/or vacuum could be applied to extract the obstruction and material from the vicinity of the gland opening. In addition, depending upon the obstruction, aspiration, suction and/or vacuum alone may be sufficient to extract the obstruction.
  • Additional features may also be provided to the rollers such as a regulated heating element (not shown) which could be placed in the outer covering near the tip as shown in FIG. 6A. In addition, the roller 375 could be equipped such that ultrasonic energy could be delivered to the obstruction as discussed herein above.
  • FIG. 8 illustrates a prototype hand held suction system generally indicated at 400 that was constructed. The system comprised an AC power supply 410 which powered a suction pump 420 to which tubing 430 was connected. At the opposite end of tubing 430 a probe 440 was connected. A tip 450 having a 1 mm diameter and a 200 micron orifice was attached to the end of the probe 440. The probe end 460 was curved for ergonomic access to the gland orifice. In use, the tip 450 is placed on or proximate the gland orifice and the applied vacuum is used to collect the obstruction as it exits the orifice or may alternatively be employed to assist in expression of the obstruction.
  • FIG. 9 illustrates another prototype of a hand held apparatus generally indicated at 500 that was constructed. The system comprised a power supply 510 which powered an electromagnet (not shown) which was encased in a handle 530 that may be easily held by the clinician in one hand. A rod 540 is mounted for reciprocating motion to the output of the electromagnet. The throw or amount of movement of the rod 540 is 0.5 mm. At the end of rod 540 is mounted a back plate 550 which is substantially perpendicular to the axis of rod 540. Further, a lever 560 is pivotally mounted to rod 540 and operates to actuate a roller 570. A heating means or heater 580 was mounted in backplate 550. The heater 580 was also provided with an appropriate power source. In operation, the device is positioned such that the back plate 550 is positioned between the cornea and the back surface of the eye lid. The lever 560 is actuated such that the roller 570 comes into contact with the front surface of the eye lid. The arc of the roller is such that the eye lid is squeezed between the foregoing The clinician may elect to maintain the back plate and the roller under tension for a preselected period of time to soften the obstruction. Once the desired temperature has been reached, further pressure on the lever 560 will cause the roller to move from the bottom of the meibomian gland (the end away from the orifice) to the top of the gland to express the obstruction from the gland in am “milking type” motion. Thus, a repeatable regulated method for opening obstructed meibomian glands is provided.
  • The embodiment illustrated in FIGS. 10A through 10C, the present invention prototype is a hand held apparatus generally indicated at 600. The apparatus comprises a power source 610 which may be a DC source such as a battery or an AC source similar to those discussed herein above. The power source 610 resides within a housing 620. The power source 610 provides electrical current to a wave form generator 625 which powers an acoustic amplifier 630 (for example, a small audio speaker) also located within housing 620 and mounted at an ergonomic angle therein. The acoustic amplifier 630 is programmed to vibrate in a wave format at a frequency of 0 to 200 Hz at an amplitude in the range of 0.25 mm to 5 mm. Initial experiments indicate that free air amplitude of 3-4 mm at a frequency of 60 Hz to 125 Hz is well tolerated and after 10-30 seconds of application seems to impart a natural numbing effect to the eyelid/gland. Mounted in operative association atop the acoustic amplifier 630 is an annulus 635 that floats thereon and includes a cone shaped housing 640 extending perpendicularly away from the amplifier 625 that encloses the amplifier 625 The end of the housing 640 is adapted to mount a variety of tips 650. For example, the tip may comprise a roller 655 mounted for rotation in a cradle 665. Further, the tip 650 may be modified to include a regulated heating element (not shown) that acts to soften the obstruction. Other tip configurations may include a vacuum for collecting the obstruction after expression thereof from the gland and different tip configurations to apply various contact areas and resulting forces. Thus, it will be seen that the obstruction is actually subjected to a pair of forces, the first being the weight of the device itself on the gland which may be combined with additional pressure by the health care provider pressing on the gland plus the additional intermittent force delivered to the gland by the vibratory or pulsatory force of the tip 650. The first force may be a fixed constantly applied force or one that increases to a preselected maximum. Testing has indicated that use of the foregoing method, i.e., applying a first force to the meibomian gland and a second pulsatile force to the meibomian gland allows delivery of a greater quantity of energy to the obstruction while lowering the perceived pain level to the patient. It is believed that this is the result of an overall lower degree of localized nerve stimulation about the orbit. Heating the gland is also beneficial in the event softening of the obstruction is needed prior to expression thereof.
  • Another embodiment of the invention is shown in FIGS. 11A through 11E wherein the treatment apparatus is incorporated into a goggle-like device, termed herein as the “hydro-oculator” which is a head borne device that locates the treatment mechanism proximate the eyelids, generally indicated at 700. The hydro-oculator 700 comprises a flexible frame 705 having a headband 710 (which may be elastic) connected thereto at each end. Connected to the bottom of the frame 705 is a molded housing 720 which has an angled leg 725 which is adapted to overlie the cheek bone when the apparatus is in use. Further, an expandable fluid or gas impermeable container referred to herein as a bladder 730 is positioned within the cavity defined by the space between the housing and the lower eye lid. A pumping mechanism is provided that facilitates movement of a fluid or gas, collectively referred to herein as a “medium” (not shown) into and out of each of the respective bladders 730. According to the invention, the patient would position the hydo-oclulator 700 on his or her head such that the leg 725 of molded housing 730 rests on the upper cheek bone as best shown in FIGS. 11C through 11E. The regulated heated medium is pumped into the bladders 730 causing partial expansion thereof in order to apply a pressure to the eyelids in the range of from zero to fifty pounds per square inch (50 psi). The bladder containing the heated medium (a water based solution being preferred) is positioned on the eyelids over the meibomian glands for a preselected period of time (up to thirty minutes) to soften the obstruction. It is desirable to place the heat source in direct contact with the eyelids which thereby transmits thermal energy to the meibomian glands, in contrast to the prior art which heats a confined space in front of the open eye where heat could be transmitted to the ocular bulbi structures such as the crystalline lens which introduces the possibility of cataract formation. Thereafter, the bladder is slowly expanded to a preselected maximum such that the force on the gland increases from the bottom up to the top or orifice end of the gland such that the obstruction is expressed therefrom in a “milking” type of action. Milking may be applied at a preselected frequency between zero and five hertz (0-5 Hz) and for a preselected period of time, usually not more than thirty minutes. In addition, the medium may be “pulsed”, i.e., milkingly moved into and out of the bladder to further facilitate expression of the obstruction from the gland. Pulsing may also be achieved by providing an external force to the bladder and transmitting the force through the fluid into the gland. Pulsing may be applied at a preselected frequency between zero and one hundred hertz (0-100 Hz) for a preselected period time, usually not more than thirty (30) minutes. A chemical or pharmacological agent may be inserted into the meibomian gland to assist in softening the obstruction and any of the extraction modalities mentioned above may be further employed to assist in removing the obstruction.
  • Another embodiment of the invention may employ a chemical agent or compound to clean the glandular margin to remove or exfoliate cells from the gland orifice. A probe similar to that shown in FIG. 5 may be employed, except that the outer drum or roller will deliver the chemical agent and the suction applied by the outer covering will be used to evacuate the used chemical agent and cellular material mixture away from the gland margin. Similarly, the heating and vibrational features discussed above may also be included.
  • A further embodiment of the invention may deliver vibrational and/or thermal energy to the obstruction P without contacting the gland. One potential energy source is laser light supplied by a titanium-sapphire, argon, krypton, RF energy or microwave energy. Extraction of the obstruction would be accomplished by the means described herein above.
  • Another embodiment of the invention employs the use of chemical or pharmacological agents to open or dilate the gland and gland orifice wherein the obstruction naturally is expressed and returns the normal secretions of the gland. Alternatively, the chemical or pharmaceutical agent would be used to soften or breakup the obstruction with such obstruction being expressed with the use of devices as defined above or combinations thereof. Chemical or pharmacological agents may also be used in connection with the device for post treatment. Once the glands have been opened then chemical or pharmacological agents may be used to enhance the normal production or secretion to maintain the glands in its unblocked state.
  • Dilation of the meibomian gland channel and orifice may also be employed to loosen or free the obstruction from the gland walls. Dilation may be accomplished by chemical, pharmacological, or mechanical means.
  • Stimulation of the meibomian gland may also be employed in conjunction with the other modalities discussed above to loosen or fracture the obstruction.
  • As mentioned herein above, the present invention has been described in detail on conjunction with the figures in connection with the meibomian glands of the eye. The reader will note that the principals of this invention may be applied with equal efficacy to the other glands of the human body and potentially to valuable domesticated farm animals to treat various ailments.

Claims (30)

1. A method of treating gland dysfunction in humans wherein the flow of naturally occurring secretion from the gland is occluded due to the presence of an obstruction in the gland channel, comprising the steps of:
softening the obstruction through the application of thermal energy to the obstruction;
extracting the obstruction through the application of a regulated force to the gland.
2. The method according to claim 1 wherein the thermal energy applied heats the obstruction to between about 37° C. to about 50° C.
3. The method according to claim 1 wherein the thermal energy applied heats the obstruction to between about 42° C. to about 46° C.
4. The method according to claim 1 wherein the thermal energy,applied is selected from the group of regulated heat generating modalities consisting of conduction, convection and radiation.
5. The method according to claim 1 wherein the regulated force comprises an electro mechanical force applied to the gland.
6. The method according to claim 5 wherein the electro mechanical force is a pulsatile force.
7. The method according to claim 5 wherein the electro mechanical force is an applied pulsatile force to milkingly express the obstruction from the gland.
8. The method according to claim 7 wherein the pulsatile force is applied at a preselected frequency.
9. The method according to claim 8 wherein the preselected frequency is less than 1000 Hz.
10. The method according to claim 8 wherein the preselected frequency is between about 50 Hz and about 500 Hz.
11. The method according to claim 8 wherein the pulsatile force is delivered at a frequency of between about 60 Hz and about 300 Hz.
12. The method according to claim 9 wherein the pulsatile force has amplitude of between 0.1 mm and 5.0 mm.
13. The method according to claim 9 wherein the pulsatile force has an amplitude of between about 0.5 mm and 1.5 mm.
14. The method according to claim 9 wherein the pulsatile force has an amplitude of approximately 1.00 mm.
15. The method according to claim 1 wherein the regulated force is constantly applied and increases to a preselected maximum.
16. The method according to claim 15 further including a second pulsatile force applied to the gland.
17. The method according to claim 16 wherein the second pulsatile force is delivered at a frequency of between about 60 Hz and about 300 Hz.
18. The method according to claim 17 wherein the pulsatile force has an amplitude of between about 0.1 mm and 5.0 mm.
19. The method according to claim 1 wherein the regulated force comprises a vibrating tip applied to the gland.
20. The method according to claim 19 wherein the vibrating tip is maintained at a temperature sufficient to heat the obstruction to about 37° C. to about 55° C.
21. The method according to claim 20 wherein the first regulated force is the pressure of the tip on the eyelid and the second pulsatile force is the amplitudinal energy transferred by the tip vibrations.
22. A method of treating meibomian gland dysfunction in the human eye wherein the flow of naturally occurring secretion from the meibomian gland is occluded due to the presence of an obstruction in the gland channel, comprising the steps of:
softening the obstruction through the application of thermal energy to the obstruction to heat the obstruction to between about 37° C. to about 47° C.;
applying a regulated force to the gland; and
applying a second regulated pulsatile force to the gland to milkingly express the obstruction from the gland.
23. The method according to claim 22 wherein the respective regulated force and the second regulated forces are applied with a vibrating tip.
24. The method according to claim 23 wherein the vibrating tip is heated to transmit thermal energy to the obstruction.
25. A method of treating meibomian gland dysfunction in the human eye wherein the flow of naturally occurring secretion to the eye is occluded due to the presence of an obstruction in the meibomian gland in the eye lid and comprising the steps of:
coupling a treatment device to the eyelid;
softening the obstruction with regulated heat; and
applying a regulated force to the eyelid.
26. The method according to claim 25 wherein the coupled regulated energy force applied to the. eyelid surface. milkingly compresses the eyelid to express obstructive material from the meibomian gland.
27. The method according to claim 25 wherein the regulated heat energy applied is selected from the group of heat generating modalities consisting of conduction, convection and radiation.
28. The method according to claim 25 wherein the regulated heat energy is maintained by a temperature measurement and control feedback loop.
29. The method according to claim 25 wherein the step of heating further includes heating the obstruction to between about 37° C. to about 47° C.
30. An apparatus for treating meibomian gland dysfunction in the human eye wherein the flow of naturally occurring secretion from the meibomian gland is occluded due to the presence of an obstruction in the gland channel, comprising the steps of:
heating means for softening the obstruction through the application of thermal energy to the obstruction to heat the obstruction to between about 37° C. to about 47° C.;
means for applying a regulated force to the gland; and
means for applying a second regulated pulsatile force to the gland to milkingly express the obstruction from the gland.
US11/434,446 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction Abandoned US20070016256A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
US11/434,446 US20070016256A1 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction
US11/541,418 US7981145B2 (en) 2005-07-18 2006-09-29 Treatment of meibomian glands
US11/928,681 US8950405B2 (en) 2006-05-15 2007-10-30 Treatment of obstructive disorders of the eye or eyelid
US12/015,584 US8007524B2 (en) 2006-05-15 2008-01-17 Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US12/015,683 US8128674B2 (en) 2006-05-15 2008-01-17 System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,576 US7981147B2 (en) 2006-05-15 2008-01-17 Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,558 US7981146B2 (en) 2006-05-15 2008-01-17 Inner eyelid treatment for treating meibomian gland dysfunction
US12/015,675 US8128673B2 (en) 2006-05-15 2008-01-17 System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,721 US8137390B2 (en) 2006-05-15 2008-01-17 System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US12/015,567 US7976573B2 (en) 2006-05-15 2008-01-17 Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,600 US9314369B2 (en) 2006-05-15 2008-01-17 System for inner eyelid treatment of meibomian gland dysfunction
US12/015,593 US20080114423A1 (en) 2006-05-15 2008-01-17 Apparatus for inner eyelid treatment of meibomian gland dysfunction
US13/025,990 US8187311B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/025,951 US8187310B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/183,901 US9216028B2 (en) 2005-07-18 2011-07-15 Apparatuses for treatment of meibomian glands
US13/367,908 US8617229B2 (en) 2006-05-15 2012-02-07 System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US13/367,865 US8523928B2 (en) 2006-05-15 2012-02-07 System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US13/368,976 US8632578B2 (en) 2006-05-15 2012-02-08 System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US14/510,843 US20150025545A1 (en) 2006-05-15 2014-10-09 Methods and apparatuses for treatment of meibomian gland dysfunction
US14/510,863 US10376273B2 (en) 2005-07-18 2014-10-09 Methods and apparatuses for treatment of meibomian glands
US14/618,392 US20150157347A1 (en) 2005-07-18 2015-02-10 Treatment of obstructive disorders of the eye or eyelid
US15/359,856 US10952896B2 (en) 2006-05-15 2016-11-23 Methods and apparatuses for treatment of meibomian gland dysfunction
US16/358,754 US20190282251A1 (en) 2005-07-18 2019-03-20 Methods and apparatuses for treatment of meibomian glands
US17/208,465 US20210205131A1 (en) 2006-05-15 2021-03-22 Methods and apparatuses for treatment of meibomian gland dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70023305P 2005-07-18 2005-07-18
US11/434,446 US20070016256A1 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
US11/434,033 Continuation-In-Part US8915253B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction employing heated medium
US11/434,054 Continuation-In-Part US8083787B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating meibomian gland dysfunction
US11/541,308 Continuation-In-Part US20070060988A1 (en) 2005-07-18 2006-09-29 Melting meibomian gland obstructions
US11/541,291 Continuation-In-Part US7981095B2 (en) 2005-07-18 2006-09-29 Methods for treating meibomian gland dysfunction employing fluid jet

Related Child Applications (14)

Application Number Title Priority Date Filing Date
US11/434,054 Continuation-In-Part US8083787B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating meibomian gland dysfunction
US11/434,033 Continuation-In-Part US8915253B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction employing heated medium
US11/541,418 Continuation-In-Part US7981145B2 (en) 2005-07-18 2006-09-29 Treatment of meibomian glands
US11/928,681 Continuation-In-Part US8950405B2 (en) 2005-07-18 2007-10-30 Treatment of obstructive disorders of the eye or eyelid
US12/015,600 Continuation-In-Part US9314369B2 (en) 2006-05-15 2008-01-17 System for inner eyelid treatment of meibomian gland dysfunction
US12/015,567 Continuation-In-Part US7976573B2 (en) 2006-05-15 2008-01-17 Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,675 Continuation-In-Part US8128673B2 (en) 2006-05-15 2008-01-17 System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,584 Continuation-In-Part US8007524B2 (en) 2006-05-15 2008-01-17 Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US12/015,558 Continuation-In-Part US7981146B2 (en) 2005-07-18 2008-01-17 Inner eyelid treatment for treating meibomian gland dysfunction
US12/015,683 Continuation-In-Part US8128674B2 (en) 2006-05-15 2008-01-17 System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US12/015,593 Continuation-In-Part US20080114423A1 (en) 2005-07-18 2008-01-17 Apparatus for inner eyelid treatment of meibomian gland dysfunction
US12/015,721 Continuation-In-Part US8137390B2 (en) 2006-05-15 2008-01-17 System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US13/025,990 Continuation US8187311B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/025,951 Continuation US8187310B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction

Publications (1)

Publication Number Publication Date
US20070016256A1 true US20070016256A1 (en) 2007-01-18

Family

ID=39135255

Family Applications (10)

Application Number Title Priority Date Filing Date
US11/434,446 Abandoned US20070016256A1 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction
US11/434,054 Active 2030-06-07 US8083787B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating meibomian gland dysfunction
US11/434,033 Active 2030-07-27 US8915253B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction employing heated medium
US11/931,398 Active 2029-12-03 US9060843B2 (en) 2005-07-18 2007-10-31 Method and apparatus for treating gland dysfunction employing heated medium
US12/821,183 Expired - Fee Related US8025689B2 (en) 2005-07-18 2010-06-23 Method and apparatus for treating meibomian gland dysfunction
US13/025,951 Active US8187310B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/025,990 Active US8187311B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/242,068 Active US8685073B2 (en) 2005-07-18 2011-09-23 Apparatus for treating meibomian gland dysfunction
US14/746,328 Abandoned US20150283402A1 (en) 2005-07-18 2015-06-22 Methods and apparatuses for treating gland dysfunction employing heated medium
US16/375,196 Active US10905898B2 (en) 2005-07-18 2019-04-04 Methods and apparatuses for treating gland dysfunction

Family Applications After (9)

Application Number Title Priority Date Filing Date
US11/434,054 Active 2030-06-07 US8083787B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating meibomian gland dysfunction
US11/434,033 Active 2030-07-27 US8915253B2 (en) 2005-07-18 2006-05-15 Method and apparatus for treating gland dysfunction employing heated medium
US11/931,398 Active 2029-12-03 US9060843B2 (en) 2005-07-18 2007-10-31 Method and apparatus for treating gland dysfunction employing heated medium
US12/821,183 Expired - Fee Related US8025689B2 (en) 2005-07-18 2010-06-23 Method and apparatus for treating meibomian gland dysfunction
US13/025,951 Active US8187310B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/025,990 Active US8187311B2 (en) 2005-07-18 2011-02-11 Method and apparatus for treating gland dysfunction
US13/242,068 Active US8685073B2 (en) 2005-07-18 2011-09-23 Apparatus for treating meibomian gland dysfunction
US14/746,328 Abandoned US20150283402A1 (en) 2005-07-18 2015-06-22 Methods and apparatuses for treating gland dysfunction employing heated medium
US16/375,196 Active US10905898B2 (en) 2005-07-18 2019-04-04 Methods and apparatuses for treating gland dysfunction

Country Status (1)

Country Link
US (10) US20070016256A1 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051741A1 (en) * 2005-07-18 2008-02-28 Grenon Stephen M Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
WO2008024100A3 (en) * 2006-08-21 2009-04-30 Tearscience Inc Method and apparatus for treating gland dysfunction
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
US20100100029A1 (en) * 2007-11-13 2010-04-22 Steven Maskin Gland or duct diagnostic and treatment methods and related apparatus
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
US20100292630A1 (en) * 2007-11-13 2010-11-18 Maskin Steven L Meibomian Gland Intraductal Diagnostic and Treatment Methods
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20110178585A1 (en) * 2008-05-16 2011-07-21 Biser Seth A Thermal compress system and methods of using the same
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8025689B2 (en) 2005-07-18 2011-09-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US20120165708A1 (en) * 2009-06-24 2012-06-28 Colin Parsloe Massage Apparatus and Method of Use
US20130110101A1 (en) * 2011-09-08 2013-05-02 Marcia Van Valen Methods for treating eye conditions
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US9719977B2 (en) 2005-07-18 2017-08-01 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10092449B2 (en) 2013-04-30 2018-10-09 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10603210B1 (en) 2017-02-02 2020-03-31 Mgd Innovations, Llc Meibomian gland probing with blood product injection
US10835418B1 (en) 2016-09-06 2020-11-17 Sarah S. Darbandi Meibomian gland thermal treatment apparatus
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10940074B2 (en) 2005-07-18 2021-03-09 Tearscience Inc Melting meibomian gland obstructions
US10952896B2 (en) 2006-05-15 2021-03-23 Tearscience Inc Methods and apparatuses for treatment of meibomian gland dysfunction
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
CN113164283A (en) * 2018-12-06 2021-07-23 爱尔康公司 Systems and methods for treating eye conditions
US11076983B2 (en) 2008-05-16 2021-08-03 Seth A. Biser Thermal eye compress systems and methods of use

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022060A1 (en) 2000-09-15 2002-03-21 Bruder Healthcare Company Wound and therapy compress and dressing
US9925087B2 (en) 2000-09-15 2018-03-27 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
US10105259B2 (en) 2000-09-15 2018-10-23 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
US20060210616A1 (en) * 2005-03-17 2006-09-21 Linder Barry J Therapeutic patch for ophthalmologic and cosmetic use
WO2008089327A1 (en) 2007-01-17 2008-07-24 Tearscience, Inc. Methods, systems, and apparatuses for heat treatment for treating meibomian gland dysfunction
US7655004B2 (en) * 2007-02-15 2010-02-02 Ethicon Endo-Surgery, Inc. Electroporation ablation apparatus, system, and method
US20080200911A1 (en) * 2007-02-15 2008-08-21 Long Gary L Electrical ablation apparatus, system, and method
US20080200755A1 (en) * 2007-02-15 2008-08-21 Bakos Gregory J Method and device for retrieving suture tags
US20080200933A1 (en) * 2007-02-15 2008-08-21 Bakos Gregory J Surgical devices and methods for forming an anastomosis between organs by gaining access thereto through a natural orifice in the body
US7815662B2 (en) * 2007-03-08 2010-10-19 Ethicon Endo-Surgery, Inc. Surgical suture anchors and deployment device
US8075572B2 (en) 2007-04-26 2011-12-13 Ethicon Endo-Surgery, Inc. Surgical suturing apparatus
US8100922B2 (en) * 2007-04-27 2012-01-24 Ethicon Endo-Surgery, Inc. Curved needle suturing tool
US8262655B2 (en) * 2007-11-21 2012-09-11 Ethicon Endo-Surgery, Inc. Bipolar forceps
US20090062788A1 (en) * 2007-08-31 2009-03-05 Long Gary L Electrical ablation surgical instruments
US20090062795A1 (en) * 2007-08-31 2009-03-05 Ethicon Endo-Surgery, Inc. Electrical ablation surgical instruments
US8579897B2 (en) * 2007-11-21 2013-11-12 Ethicon Endo-Surgery, Inc. Bipolar forceps
US8568410B2 (en) * 2007-08-31 2013-10-29 Ethicon Endo-Surgery, Inc. Electrical ablation surgical instruments
US20090112063A1 (en) * 2007-10-31 2009-04-30 Bakos Gregory J Endoscopic overtubes
US8480657B2 (en) 2007-10-31 2013-07-09 Ethicon Endo-Surgery, Inc. Detachable distal overtube section and methods for forming a sealable opening in the wall of an organ
US20090131751A1 (en) * 2007-11-20 2009-05-21 Spivey James T Anal surgical instrument guides
GB0722890D0 (en) * 2007-11-21 2008-01-02 Innovative Treat Solutions Ltd Apparatus and method of massage
US20090143794A1 (en) * 2007-11-29 2009-06-04 Conlon Sean P Tissue resection device
US8262680B2 (en) * 2008-03-10 2012-09-11 Ethicon Endo-Surgery, Inc. Anastomotic device
US20090287236A1 (en) * 2008-05-16 2009-11-19 Ethicon Endo-Surgery, Inc. Endoscopic rotary access needle
US8070759B2 (en) * 2008-05-30 2011-12-06 Ethicon Endo-Surgery, Inc. Surgical fastening device
US8652150B2 (en) 2008-05-30 2014-02-18 Ethicon Endo-Surgery, Inc. Multifunction surgical device
US8771260B2 (en) * 2008-05-30 2014-07-08 Ethicon Endo-Surgery, Inc. Actuating and articulating surgical device
US8114072B2 (en) * 2008-05-30 2012-02-14 Ethicon Endo-Surgery, Inc. Electrical ablation device
US8679003B2 (en) * 2008-05-30 2014-03-25 Ethicon Endo-Surgery, Inc. Surgical device and endoscope including same
US8317806B2 (en) * 2008-05-30 2012-11-27 Ethicon Endo-Surgery, Inc. Endoscopic suturing tension controlling and indication devices
US8906035B2 (en) 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
US8403926B2 (en) * 2008-06-05 2013-03-26 Ethicon Endo-Surgery, Inc. Manually articulating devices
US20100010303A1 (en) * 2008-07-09 2010-01-14 Ethicon Endo-Surgery, Inc. Inflatable access device
US8262563B2 (en) * 2008-07-14 2012-09-11 Ethicon Endo-Surgery, Inc. Endoscopic translumenal articulatable steerable overtube
US8888792B2 (en) 2008-07-14 2014-11-18 Ethicon Endo-Surgery, Inc. Tissue apposition clip application devices and methods
US8529563B2 (en) * 2008-08-25 2013-09-10 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US8241204B2 (en) * 2008-08-29 2012-08-14 Ethicon Endo-Surgery, Inc. Articulating end cap
US8409200B2 (en) 2008-09-03 2013-04-02 Ethicon Endo-Surgery, Inc. Surgical grasping device
US8114119B2 (en) * 2008-09-09 2012-02-14 Ethicon Endo-Surgery, Inc. Surgical grasping device
US8337394B2 (en) * 2008-10-01 2012-12-25 Ethicon Endo-Surgery, Inc. Overtube with expandable tip
US8157834B2 (en) * 2008-11-25 2012-04-17 Ethicon Endo-Surgery, Inc. Rotational coupling device for surgical instrument with flexible actuators
US20100152539A1 (en) * 2008-12-17 2010-06-17 Ethicon Endo-Surgery, Inc. Positionable imaging medical devices
US8828031B2 (en) * 2009-01-12 2014-09-09 Ethicon Endo-Surgery, Inc. Apparatus for forming an anastomosis
US8361066B2 (en) * 2009-01-12 2013-01-29 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US20100191050A1 (en) * 2009-01-23 2010-07-29 Ethicon Endo-Surgery, Inc. Variable length accessory for guiding a flexible endoscopic tool
US20100191267A1 (en) * 2009-01-26 2010-07-29 Ethicon Endo-Surgery, Inc. Rotary needle for natural orifice translumenal endoscopic surgery
US9226772B2 (en) 2009-01-30 2016-01-05 Ethicon Endo-Surgery, Inc. Surgical device
US8037591B2 (en) * 2009-02-02 2011-10-18 Ethicon Endo-Surgery, Inc. Surgical scissors
US20100298642A1 (en) * 2009-05-19 2010-11-25 Ethicon Endo-Surgery, Inc. Manipulatable guide system and methods for natural orifice translumenal endoscopic surgery
US20110098694A1 (en) * 2009-10-28 2011-04-28 Ethicon Endo-Surgery, Inc. Methods and instruments for treating cardiac tissue through a natural orifice
US20110098704A1 (en) 2009-10-28 2011-04-28 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US20110115891A1 (en) * 2009-11-13 2011-05-19 Ethicon Endo-Surgery, Inc. Energy delivery apparatus, system, and method for deployable medical electronic devices
US8721572B1 (en) 2010-06-10 2014-05-13 Eyedetec Medical, Inc. Systems, devices, kits and methods for therapy of the eye
US8491508B2 (en) * 2010-09-15 2013-07-23 Walton F. Smith Device and method for stimulating the meibomian glands of the eyelid
CA2817589A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US9254169B2 (en) 2011-02-28 2016-02-09 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
US9233241B2 (en) 2011-02-28 2016-01-12 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
WO2013006574A1 (en) * 2011-07-01 2013-01-10 Vanderbilt University Surfactant ported device for treatment of blepharitis and applications of same
US9333370B2 (en) * 2011-12-07 2016-05-10 Lumenis Ltd. Apparatus and method for applying light in ocular and periocular areas
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
US9724230B2 (en) * 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
JP2015509022A (en) 2012-02-03 2015-03-26 アイ コンフォート リミテッド Eye massager
CA2869408C (en) 2012-04-05 2021-02-02 Matthew BUJAK Method, system and use for therapeutic ultrasound
US10085879B2 (en) 2012-04-17 2018-10-02 Empire Technology Development, Llc Heat treatment device
US9427255B2 (en) 2012-05-14 2016-08-30 Ethicon Endo-Surgery, Inc. Apparatus for introducing a steerable camera assembly into a patient
US9039718B2 (en) * 2012-07-24 2015-05-26 Blephex, Llc Method and device for treating an ocular disorder
US20140214062A1 (en) * 2012-07-24 2014-07-31 James RYNERSON Method and device for treating an ocular disorder
EA031138B1 (en) 2012-07-24 2018-11-30 БЛЕФЕКС, ЭлЭлСи Method and device for removal of foreign bodies from edge of eyelid
CA2878078A1 (en) * 2012-07-25 2014-01-30 Rolando TOYOS Selected light wavelengths and delivery devices for the prevention and treatment of dry eye syndrome
US9545290B2 (en) 2012-07-30 2017-01-17 Ethicon Endo-Surgery, Inc. Needle probe guide
US10314649B2 (en) 2012-08-02 2019-06-11 Ethicon Endo-Surgery, Inc. Flexible expandable electrode and method of intraluminal delivery of pulsed power
US9277957B2 (en) 2012-08-15 2016-03-08 Ethicon Endo-Surgery, Inc. Electrosurgical devices and methods
JP5503090B1 (en) * 2012-09-28 2014-05-28 積水化学工業株式会社 Laminated glass interlayer film and laminated glass
US10039932B2 (en) * 2012-11-20 2018-08-07 Biolase, Inc. Eyelid treatment device
US10098527B2 (en) 2013-02-27 2018-10-16 Ethidcon Endo-Surgery, Inc. System for performing a minimally invasive surgical procedure
WO2014143139A1 (en) 2013-03-15 2014-09-18 Bruder Healthcare Company Wound and therapy compress and dressing
NZ745920A (en) 2013-04-19 2020-01-31 Oculeve Inc Nasal stimulation devices and methods
US10130507B2 (en) 2013-08-03 2018-11-20 Michael C. Whitehurst Dry eye treatment device
US10314763B2 (en) * 2013-12-31 2019-06-11 Teeny Clean, Llc Eyelid care appliance
CN111298285A (en) 2014-02-25 2020-06-19 奥库利维公司 Polymer formulations for nasolacrimal stimulation
EP3673952A1 (en) 2014-07-25 2020-07-01 Oculeve, Inc. Stimulation patterns for treating dry eye
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2016065211A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
AU2015335776B2 (en) 2014-10-22 2020-09-03 Oculeve, Inc. Stimulation devices and methods for treating dry eye
WO2016179369A1 (en) 2015-05-07 2016-11-10 Impact Labs Llc Device for minimizing impact of collisions for a helmet
CA2989814A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of Colorado, A Body Corporate Nasolacrimal implants and related methods for tear stimulation
US20170014300A1 (en) * 2015-06-18 2017-01-19 Eyedetec Medical, Inc. Moldable heater with Miniature Resonant Frequency Vibration Generator for Ophthalmic Eyelid Therapy
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
EP3313413A4 (en) 2015-09-28 2018-07-11 Azura Opthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
US11826279B2 (en) 2016-03-08 2023-11-28 Ken DauSchmidt Eyelid treatment device and associated methods
EP3708111A1 (en) 2016-03-22 2020-09-16 DENTSPLY SIRONA Inc. Method and arrangement for cleaning of a canal
US20170273823A1 (en) * 2016-03-23 2017-09-28 MG Therapies, Inc. System for providing interval thermal therapy
US10695219B2 (en) 2016-04-08 2020-06-30 ThermiGen, LLC Apparatus and method for treatment of dry eye using radio frequency heating
CA3019349A1 (en) 2016-04-14 2017-10-19 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US10918864B2 (en) * 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
WO2018039729A1 (en) * 2016-08-31 2018-03-08 Centre For Eye Research Australia Limited Ultrasound apparatus and system
CN110381900B (en) * 2016-10-14 2022-06-03 欧灵比克眼科公司 A hand-held device for stimulating tear production of patient
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
RU2019118600A (en) 2016-12-02 2021-01-11 Окулив, Инк. APPARATUS AND METHOD FOR MAKING DRY EYE SYNDROME PREDICTION AND TREATMENT RECOMMENDATIONS
US11517473B2 (en) * 2017-08-27 2022-12-06 Solana Hesith, Inc. Multi-modal thermal therapy for blepharitis, meibomian gland dysfunction and dry eye syndrome
CN109419578A (en) * 2017-09-01 2019-03-05 喻志平 Scheroma (MGD) intelligence thermal pulse physical therapy health-care instrument
WO2019055374A1 (en) * 2017-09-12 2019-03-21 Reichert, Inc. Rebound tonometer having tilt correction
US11141348B2 (en) 2018-02-26 2021-10-12 Olympic Ophthalmics, Inc. Treatment methods using handheld devices for disorders
WO2020130176A1 (en) * 2018-12-19 2020-06-25 부산대학교 산학협력단 Dry eye syndrome treatment device
IL267166B (en) 2019-06-06 2022-06-01 Novoxel Ltd System and method for treating blepharitis by generating skin tissue lesions
WO2021087365A1 (en) * 2019-11-01 2021-05-06 Oculeve, Inc. Charging case for handheld nasal stimulator
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd Instructions for composition and sensitivity
CN113081139B (en) * 2021-05-12 2022-02-01 郑州市中心医院 Extrusion device used after meibomian cyst extirpation

Citations (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006945A (en) * 1910-07-22 1911-10-24 James D Houston Eye-bathing mask.
US1924315A (en) * 1930-08-27 1933-08-29 Edward C Hemphill Sleep eye shade
US2891252A (en) * 1956-06-01 1959-06-23 Lazo Mario Sleeping device
US3333586A (en) * 1966-11-14 1967-08-01 Bellis Ted Eye-care devices
US4261364A (en) * 1979-01-26 1981-04-14 Haddad Heskel M Electric warm compress for ophthalmic treatment
US4778457A (en) * 1986-11-06 1988-10-18 York Kenneth K Disposable applicator
US4883454A (en) * 1987-09-04 1989-11-28 Sol Hamburg Eyelid and anterior orbit swab
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4955377A (en) * 1988-10-28 1990-09-11 Lennox Charles D Device and method for heating tissue in a patient's body
US5030214A (en) * 1990-11-01 1991-07-09 Larry Spector Ocular delivery system
US5151100A (en) * 1988-10-28 1992-09-29 Boston Scientific Corporation Heating catheters
US5158082A (en) * 1990-08-23 1992-10-27 Spacelabs, Inc. Apparatus for heating tissue with a photoplethysmograph sensor
US5251627A (en) * 1991-06-27 1993-10-12 Morris Donald E Non-invasive measurement of eyeball pressure using vibration
US5283063A (en) * 1992-01-31 1994-02-01 Eagle Vision Punctum plug method and apparatus
US5343561A (en) * 1989-08-17 1994-09-06 Adamo Ren E Sleeping mask and neck rest
US5368582A (en) * 1992-08-10 1994-11-29 The Schepens Eye Research Institute Method and apparatus for introducing fluid material into an eye
US5425380A (en) * 1991-05-31 1995-06-20 Kimberly-Clark Corporation Surgical eye mask
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5601548A (en) * 1994-11-07 1997-02-11 Ophthalmic International, L.L.C. Open angle glaucoma treatment apparatus and method
US5643336A (en) * 1995-01-09 1997-07-01 Lopez-Claros; Marcelo Enrique Heating and cooling pad
US5700238A (en) * 1996-07-25 1997-12-23 Hyson; Morton Isaac Device and method for treatment of headache
US5807357A (en) * 1997-08-19 1998-09-15 Kang; Meng-Che Compact nebulizer for treating the eyes
US5836927A (en) * 1996-10-07 1998-11-17 Fried; George Device to aid in the self administration of eyedrops
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5964723A (en) * 1992-06-19 1999-10-12 Augustine Medical, Inc. Normothermic tissue heating wound covering
US6024095A (en) * 1998-04-10 2000-02-15 Proteus Therapeutics, Inc. Corneal heat and stretch method and apparatus
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US6110292A (en) * 1997-08-12 2000-08-29 Warren R. Jewett Oscillating liquid jet washing system
US6112900A (en) * 1998-07-01 2000-09-05 Ocusoft, Inc. Care kit for contact lens wearers
US6153607A (en) * 1995-12-04 2000-11-28 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
US6155995A (en) * 1999-08-05 2000-12-05 Lin; Pin-Hung Structure of a multifunctional eye mask
US6181970B1 (en) * 1999-02-09 2001-01-30 Kai Technologies, Inc. Microwave devices for medical hyperthermia, thermotherapy and diagnosis
US6193740B1 (en) * 1997-12-19 2001-02-27 Andrea Janine Rodriguez Eye pillows with adjustable strap
US6206842B1 (en) * 1998-08-03 2001-03-27 Lily Chen Tu Ultrasonic operation device
US20010041886A1 (en) * 1999-12-10 2001-11-15 Durkin Anthony J. Method of treating disorders associated with sebaceous follicles
US20020035345A1 (en) * 1999-05-25 2002-03-21 Beck Jon E. Methods and apparatus for ocular iontophopesis
US20020099094A1 (en) * 2000-08-16 2002-07-25 Anderson Richard Rox Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris
US6425888B1 (en) * 1994-08-30 2002-07-30 R. P. Scherer Corporation Ocular treatment device
US20020111608A1 (en) * 2001-01-18 2002-08-15 George Baerveldt Minimally invasive glaucoma surgical instrument and method
US6438398B1 (en) * 1999-03-05 2002-08-20 The University Of Miami Process and device for measuring tear fluorescein clearance
US20020128696A1 (en) * 2001-03-06 2002-09-12 Henry Pearl Apparatus and method for stimulating hair growth
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US6482203B2 (en) * 1997-09-30 2002-11-19 Scimed Life Systems, Inc. Deflectable interstitial ablation device
US6490488B1 (en) * 1998-12-11 2002-12-03 Urologix, Inc. Method of controlling thermal therapy
US20030056281A1 (en) * 2001-09-26 2003-03-27 Tokuichiro Hasegawa Eye mask
US20030065277A1 (en) * 1999-01-21 2003-04-03 Chandice Covington Method and apparatus for measuring factors in mammary fluids
US20030139790A1 (en) * 1997-08-13 2003-07-24 Surx, Inc. Noninvasive devices, methods, and systems for shrinking of tissues
US20030195438A1 (en) * 2002-04-12 2003-10-16 Petillo Phillip J. Method and apparatus to treat glaucoma
US6641264B1 (en) * 2002-04-15 2003-11-04 Mary Schwebel Remedy for dry eye syndrome
US20030211043A1 (en) * 2001-09-28 2003-11-13 Korb Donald R. Eye treatment
US20030233135A1 (en) * 2002-06-14 2003-12-18 Yee Richard W. Method and apparatus for preventing and treating eyelid problems
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20040153093A1 (en) * 2003-01-31 2004-08-05 Advanced Medical Optics, Inc. Bi-manual phacoemulsification apparatus and method
US6788977B2 (en) * 2000-06-20 2004-09-07 Celsion Corporation System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumor
US20040237969A1 (en) * 2002-01-24 2004-12-02 Fuller John Robert Therapeutic eye and eye lid cover
US6827898B1 (en) * 1999-05-25 2004-12-07 Viacirq, Inc. Hyperthermia method and apparatus
US6840954B2 (en) * 2001-12-20 2005-01-11 Solarant Medical, Inc. Systems and methods using vasoconstriction for improved thermal treatment of tissues
US20050022823A1 (en) * 2003-07-30 2005-02-03 Suzanne Davison Apparatus, system and method for treating dry eye conditions and promoting healthy eyes
US6860880B2 (en) * 1997-03-05 2005-03-01 The Trustees Of Columbia University In The City Of New York Electrothermal instrument for sealing and joining or cutting tissue
US6860852B2 (en) * 2002-10-25 2005-03-01 Compex Medical S.A. Ultrasound therapeutic device
US6882885B2 (en) * 2002-03-19 2005-04-19 Solarant Medical, Inc. Heating method for tissue contraction
US20050119629A1 (en) * 2003-12-01 2005-06-02 Soroudi Abraham E. Device and method for exothermic treatment of eyelid diseases
US6925317B1 (en) * 1999-06-11 2005-08-02 Spectrx, Inc. Integrated alignment devices, system, and methods for efficient fluid extraction, substance delivery and other applications
US20050220742A1 (en) * 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
US6974454B2 (en) * 2000-04-27 2005-12-13 Atricure, Inc. Transmural ablation device with thermocouple for measuring tissue temperature
US20060018953A1 (en) * 2002-11-05 2006-01-26 Michel Guillon Eyelid margin wipes comprising chemical means for temperature adjustment
US20060030604A1 (en) * 2001-11-08 2006-02-09 Magdalena Elsinger Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US7001379B2 (en) * 1999-06-25 2006-02-21 Boston Scientific Scimed, Inc. Method and system for heating solid tissue
US7004942B2 (en) * 1998-01-14 2006-02-28 Solarant Medical, Inc. Ribbed electrodes and methods for their use
US20060104914A1 (en) * 2004-03-12 2006-05-18 Soroudi Abraham E Device and method for treatment of eyelid diseases
US20060183698A1 (en) * 2004-06-07 2006-08-17 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US7108694B2 (en) * 2002-11-08 2006-09-19 Olympus Corporation Heat-emitting treatment device
US7118591B2 (en) * 2003-04-17 2006-10-10 The University Of Chicago Heat transfer probe
US7123968B1 (en) * 1996-09-20 2006-10-17 The Board Of Regents Of The University Of Texas System Heat treatment of inflamed tissue
US20060233859A1 (en) * 2004-04-30 2006-10-19 Allergan, Inc. Methods for treating retinopathy with extended therapeutic effect
US20070049913A1 (en) * 2005-07-18 2007-03-01 Grenon Stephen M Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US20070280924A1 (en) * 2004-03-02 2007-12-06 Julie Daniels Pharmaceutical Preparations For And Treatment Of Ocular Surface and Other Disorders
US20080051741A1 (en) * 2005-07-18 2008-02-28 Grenon Stephen M Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US20080075787A1 (en) * 2004-11-25 2008-03-27 Sawako Hibino Therapeutic Agent For Ophthalmic Diseases
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US168352A (en) 1875-10-05 Improvement in apparatus for thawing frozen water-pipes
US2545724A (en) 1948-06-08 1951-03-20 Curtis Cecil Claud Applicator for heat manipulation of the eyes
US3173419A (en) 1962-07-10 1965-03-16 Dubilier William Relaxer device
US3140390A (en) 1963-06-12 1964-07-07 Smith Percy Therapeutic appliance
US3404678A (en) 1965-08-13 1968-10-08 Ardenne Manfred Von Device for performing an extreme hyperthermia treatment
US3403468A (en) 1966-05-16 1968-10-01 Louis F. Bartoletti Removable fishing rod guide
US3415299A (en) 1966-11-21 1968-12-10 American Hospital Supply Corp Bottom emptying urine collection container
US3667476A (en) 1970-04-27 1972-06-06 Bio Data Corp Apparatus for monitoring body temperature and controlling a heating device to maintain a selected temperature
GB1424121A (en) 1973-01-04 1976-02-11 Plastitherm Ltd Adhesive block for use in adhesive dispensing devices
US3952735A (en) 1975-05-27 1976-04-27 Wirtschafter Jonathan D Eye bandage
US4029757A (en) 1975-12-15 1977-06-14 Hoffmann-La Roche Inc. Manufacture of pharmaceutical unit dosage forms
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4958632A (en) 1978-07-20 1990-09-25 Medtronic, Inc. Adaptable, digital computer controlled cardiac pacemaker
US4387707A (en) 1981-05-14 1983-06-14 Polikoff Lawrence A Eye treatment device and method
US4612959A (en) 1985-05-07 1986-09-23 Mobil Oil Corporation Valveless shut-off and transfer device
US4784165A (en) * 1986-03-07 1988-11-15 Stein Robert F Eyelash curler
US4918818A (en) 1988-09-22 1990-04-24 Hsieh Yin Fei Multi-purpose massage shaver
JP2876218B2 (en) 1989-08-11 1999-03-31 小林製薬株式会社 Eye mask
US5213097A (en) 1989-10-24 1993-05-25 Zewa Ag Apparatus for the treatment of diseases of the walls of opening or cavities of the body
US5020455A (en) 1990-01-11 1991-06-04 Chiba City & Tsukishima Kikai Kubushiki Kaisha System for treating waste material in a molten state
US5097829A (en) 1990-03-19 1992-03-24 Tony Quisenberry Temperature controlled cooling system
US5169384A (en) 1991-08-16 1992-12-08 Bosniak Stephen L Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
CN1056276C (en) 1992-03-23 2000-09-13 方存云 Suction-kneading massage device for beauty-care
US5690608A (en) * 1992-04-08 1997-11-25 Asec Co., Ltd. Ultrasonic apparatus for health and beauty
US5327886A (en) 1992-08-18 1994-07-12 Chiu Cheng Pang Electronic massage device with cold/hot compress function
USD352106S (en) 1992-09-02 1994-11-01 Alcon Laboratories, Inc. Surgical console for ophthalmic surgery
JPH06269473A (en) 1993-03-19 1994-09-27 Santen Pharmaceut Co Ltd Portable eye part warmer
US5314456A (en) 1993-03-19 1994-05-24 Cohen Gary M Therapeutic pad for relief of headache-related head, temple, neck and back pain
JPH06315499A (en) 1993-05-07 1994-11-15 Shoji Fukumoto Quiet sleep mask
US20020042612A1 (en) 1997-10-27 2002-04-11 Hood Larry L. Method and apparatus for modifications of visual acuity by thermal means
US5795312A (en) 1993-09-27 1998-08-18 The Kendall Company Compression sleeve
US5419772A (en) 1993-09-29 1995-05-30 Teitz; Bernard R. Surgical irrigation apparatus for cleaning and sterilizing wounds and surgical areas during surgery
US6041821A (en) 1994-02-04 2000-03-28 Grossman; Kurt L. Frozen pipe thawing system
JP3642812B2 (en) * 1994-11-17 2005-04-27 株式会社町田製作所 Medical observation device
GB2303208B (en) * 1995-07-08 1998-01-21 Akio Usui Viscous liquid exothermic composition,exothermic device made thereof and manufacturing method of exothermic device
US5628772A (en) 1995-12-14 1997-05-13 R-Jayco Ltd., Inc. Therapeutic massage mask
US5769806A (en) 1996-03-01 1998-06-23 Radow; Brett K. Adjustable pressure eye patch
FR2746271B1 (en) 1996-03-20 1998-07-10 Ronic Ind DERIDING DEVICE
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
JPH1085248A (en) 1996-09-13 1998-04-07 Nobel Igaku Kenkyusho:Kk Eye function improving warmer
FI102366B1 (en) 1996-11-18 1998-11-30 Valmet Corp Method and system for placing internal end plates on the ends of reels
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
US6007501A (en) 1997-01-21 1999-12-28 Cabados; Rick Henry Therapeutic massaging apparatus
EP1007038A2 (en) 1997-08-21 2000-06-14 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
JPH11221247A (en) 1997-08-25 1999-08-17 Seputo:Kk Heating glasses
EP2055254B1 (en) 1997-10-23 2015-01-14 ArthroCare Corporation Power supply for electrosurgery
US5893719A (en) * 1997-10-29 1999-04-13 Radow; Brett K. Variable pathological and surgical eye model and method related thereto
FR2772263B1 (en) 1997-12-16 2000-02-11 Seb Sa SKIN SUCTION AND MASSAGE APPARATUS
US6273886B1 (en) 1998-02-19 2001-08-14 Curon Medical, Inc. Integrated tissue heating and cooling apparatus
AU3363999A (en) 1998-03-27 1999-10-18 General Hospital Corporation, The Method and apparatus for the selective targeting of lipid-rich tissues
US6095992A (en) 1998-04-06 2000-08-01 Augustine Medical, Inc. Wound treatment apparatus for normothermic treatment of wounds
US6569189B1 (en) 1998-04-06 2003-05-27 Augustine Medical, Inc. Tissue treatment apparatus including a bandpass filter transparent to selected wavelengths of IR electromagnetic spectrum
US20020156402A1 (en) 1998-06-16 2002-10-24 Philippe-Guy E. Woog Sonic therapeutic machine for the body
US6035236A (en) 1998-07-13 2000-03-07 Bionergy Therapeutics, Inc. Methods and apparatus for electrical microcurrent stimulation therapy
CA2301110A1 (en) 1998-09-09 2000-03-09 Dante International Consulting, Inc. Facial iron
JP2000225141A (en) 1999-02-04 2000-08-15 Seputo:Kk Battery warming type eye mask
JP3112008B2 (en) 1999-05-24 2000-11-27 株式会社日立製作所 ATM communication device and traffic control method therefor
US6302901B1 (en) 1999-12-28 2001-10-16 Yi-Jen Lu Apparatus for thermal low periodic wave treatment
JP2001276113A (en) 2000-03-29 2001-10-09 Toshihiro Kuribayashi Asthenopia and visual acuity lowering preventing tool
US20010039442A1 (en) 2000-05-06 2001-11-08 Sal Gorge Headache relief device
USD456079S1 (en) 2000-05-17 2002-04-23 Cbc Kabushiki Kaisha Upright mirror with a liquid crystal display screen
CA2446143C (en) 2000-05-19 2010-01-19 Michael S. Berlin Delivery system and method of use for the eye
US6544257B2 (en) 2000-07-03 2003-04-08 Olympus Optical Co., Ltd. Thermal treatment apparatus
JP3690258B2 (en) 2000-09-05 2005-08-31 花王株式会社 Meibomian gland function improvement treatment tool
CN1297719A (en) 2000-12-09 2001-06-06 宫一青 Electrothermal device for treating eye disease
US7981063B1 (en) 2001-01-05 2011-07-19 Butler Charles F Method of simulated wave massage of the body
US7108683B2 (en) 2001-04-30 2006-09-19 Kci Licensing, Inc Wound therapy and tissue management system and method with fluid differentiation
US6706001B2 (en) 2001-05-11 2004-03-16 Bernard B. Fresco Dual tonometer pressure measurement device
US20040260209A1 (en) 2003-06-23 2004-12-23 Engli (2001) Ltd. System and method for face and body treatment
US20030073987A1 (en) 2001-10-16 2003-04-17 Olympus Optical Co., Ltd. Treating apparatus and treating device for treating living-body tissue
JP3613634B2 (en) 2001-11-06 2005-01-26 得一郎 長谷川 Vision correction device
US20050149006A1 (en) 2001-11-07 2005-07-07 Peyman Gholam A. Device and method for reshaping the cornea
US6648904B2 (en) 2001-11-29 2003-11-18 Palomar Medical Technologies, Inc. Method and apparatus for controlling the temperature of a surface
DE10206257C1 (en) 2002-02-15 2003-06-26 Beiersdorf Ag Massage system for applying preparation with e.g. analgesic or heating effect to the skin, comprising active preparation reservoir, massaging device and contact surface adjusting system
USD472637S1 (en) 2002-03-28 2003-04-01 Welch Allyn, Inc. Eye disease screening instrument
US20040064169A1 (en) 2002-09-30 2004-04-01 Briscoe Kathleen E. User interface for medical device
US7087075B2 (en) 2002-09-30 2006-08-08 Medtronic Emergency Response Systems, Inc. Feedback system for rapid induction of mild hypothermia
US6887263B2 (en) 2002-10-18 2005-05-03 Radiant Medical, Inc. Valved connector assembly and sterility barriers for heat exchange catheters and other closed loop catheters
USD477084S1 (en) 2002-12-16 2003-07-08 Alcon, Inc. Diagnostic console
US7097655B2 (en) 2003-01-17 2006-08-29 Tzu-Chen Cheng Electric heat therapy technique and instrument
WO2004066899A2 (en) 2003-01-24 2004-08-12 Engii (2001) Ltd. System and method for face and body treatment
JP4273485B2 (en) 2003-05-28 2009-06-03 長谷川 得一郎 Vision correction jig
US7013751B2 (en) 2003-05-29 2006-03-21 Shimano Inc. Bicycle shift control device
US20040249427A1 (en) 2003-06-06 2004-12-09 Yunes Nabilsi Medical cooler device
CN2650737Y (en) 2003-09-02 2004-10-27 赵清福 Myopia physiotherapeutical equipments
US7122047B2 (en) 2003-11-14 2006-10-17 The Board Of Trustees Of The Leland Stanford Junior University Controlled heat transfer with mammalian bodies
CN1631344A (en) 2003-12-24 2005-06-29 邵帅 Magnetic soft pressing type cornea moulding hypometropia correcting and curing appliance capable of tuning energy and impulse frequency
WO2005082301A1 (en) 2004-02-23 2005-09-09 Aqueduct Medical, Inc. Temperature-controllable device
JP2005237724A (en) 2004-02-27 2005-09-08 Eiichi Haba Heating eye mask
US8455016B2 (en) 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
DE102004033637B4 (en) 2004-03-23 2012-07-26 Wilfried Hatzack Holding device for milking cup with a drive for generating a movement
US20050234506A1 (en) 2004-04-15 2005-10-20 Weser Rubin G Blepharitz eyelid compressor
US7300151B2 (en) 2004-08-30 2007-11-27 Seefit Incorporated Apparatus and method for eye comfort
US7384405B2 (en) 2004-09-10 2008-06-10 Rhoades Dean L Oxygenating cosmetic instrument having various numbers of heads
US7771342B2 (en) 2004-09-29 2010-08-10 Patrick J. Rademacher Apparatus and method for reducing vision problems as a result of floaters
US8262715B2 (en) 2004-11-23 2012-09-11 Eye Delivery System, Llc Medical device and method for temperature control and treatment of the eye and surrounding tissues via magnetic drug therapy
US20070282282A1 (en) 2004-11-23 2007-12-06 Wong Edward K Jr Medical device and method for temperature control and treatment of the eye and surrounding tissues
US7229468B2 (en) 2004-11-23 2007-06-12 Wong Jr Edward K Medical device and method for temperature control and treatment of the eye and surrounding tissues
CN1781466A (en) 2004-12-03 2006-06-07 上海市杨浦区民办华都医院 Safety quality control system and method for excimer laser operation of ophthalmology
TWM269064U (en) 2004-12-21 2005-07-01 Ma-Li Tsai Adjustable shield body of eyes massage device
ES2383376T3 (en) 2005-01-18 2012-06-20 Alma Lasers Ltd Improved system to heat biological tissue using RF energy
JP2006198249A (en) 2005-01-21 2006-08-03 Rohto Pharmaceut Co Ltd Dry eye treatment tool
TWI290463B (en) 2005-03-04 2007-12-01 Bing-Hung Lin Structure of massager
US7122013B2 (en) 2005-03-14 2006-10-17 Hsing Chuan Liu Eyes massage device
JP3112008U (en) 2005-04-26 2005-07-28 栄信産業株式会社 Desorption eyewash device
WO2006118226A1 (en) 2005-04-28 2006-11-09 21Refresh Co., Ltd. Warm moxibustion unit
ATE537864T1 (en) 2005-06-02 2012-01-15 Ads & B Invest Fund L P VIBRATION DEVICE FOR TREATING NASAL CONGESTION AND SINUSITIS SYMPTOMS
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
WO2008024100A2 (en) 2006-08-21 2008-02-28 Tearscience, Inc. Method and apparatus for treating gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US8255039B2 (en) 2006-09-29 2012-08-28 Tearscience, Inc. Meibomian gland illuminating and imaging
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
DE202005011496U1 (en) 2005-07-21 2006-07-13 P & P Group Gmbh Stress relaxation device comprises opaque diver eye glass mask, mask interior, control devices coupled with production device for air pressure, heat and/or vibrations in the mask and/or the mask interior, and magnetic/magnetizable component
US20070173799A1 (en) 2005-09-01 2007-07-26 Hsia James C Treatment of fatty tissue adjacent an eye
CN2855388Y (en) 2005-09-14 2007-01-10 程昌胜 Health eye-cells
USD546459S1 (en) 2005-11-25 2007-07-10 Kabushiki Kaisha Toshiba Monitor for an ultrasonic diagnosis apparatus
WO2007061094A1 (en) 2005-11-28 2007-05-31 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
EP1968427A2 (en) 2005-12-16 2008-09-17 Novavision, Inc. Adjustable device for vision testing and therapy
USD553750S1 (en) 2006-04-11 2007-10-23 Kabushiki Kaisha Topcon Controller for ophthalmic instrument
USD552736S1 (en) 2006-05-02 2007-10-09 Kabushiki Kaisha Topcon Ophthalmic instrument
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7811252B2 (en) 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US8202853B2 (en) 2006-11-03 2012-06-19 Ocusoft, Inc. Convenience kit for eyelid treatment
US9135810B2 (en) 2006-11-28 2015-09-15 Medallion Therapeutics, Inc. Method, apparatus and system for assigning remote control device to ambulatory medical device
CN102697593B (en) 2007-01-09 2014-12-24 眼泪科学公司 Device for treating meibomian glands
CN102697595B (en) 2007-01-09 2014-12-24 眼泪科学公司 Device for treating meibomian gland
WO2008089327A1 (en) 2007-01-17 2008-07-24 Tearscience, Inc. Methods, systems, and apparatuses for heat treatment for treating meibomian gland dysfunction
US8435234B2 (en) 2007-02-06 2013-05-07 Reliant Technologies, Inc. Method and apparatus for monitoring and controlling laser-induced tissue treatment
US20080312194A1 (en) 2007-02-28 2008-12-18 Ousler Iii George W Methods and compositions for normalizing meibomian gland secretions
US20080221649A1 (en) 2007-03-09 2008-09-11 Agustina Echague Method of sequentially treating tissue
US20080251085A1 (en) 2007-04-11 2008-10-16 Mary Schwebel Disposable sleep mask for treating dry eye syndrome
ES2393424T3 (en) 2007-05-21 2012-12-21 Senju Pharmaceutical Co., Ltd. Pharmaceutical agent containing a PPAR-delta agonist
US20110273550A1 (en) 2007-08-16 2011-11-10 Shiro Amano Meibomian gland observing device
WO2009064834A2 (en) 2007-11-13 2009-05-22 Maskin Steven L Meibomian gland intraductal diagnostic and treatment methods and related apparatus
US9510844B2 (en) 2007-11-13 2016-12-06 Mgd Innovations, Llc Gland or duct diagnostic and treatment methods and related apparatus
US20090149930A1 (en) 2007-12-07 2009-06-11 Thermage, Inc. Apparatus and methods for cooling a treatment apparatus configured to non-invasively deliver electromagnetic energy to a patient's tissue
AU2008341543B2 (en) 2007-12-21 2013-05-30 Sifi Medtech S.R.L. Dual scheimpflug system for three- dimensional analysis of an eye
AU2009228205A1 (en) 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
USD612941S1 (en) 2008-03-28 2010-03-30 Reliant Technologies, Inc. Dermatological optical delivery system
ES2530723T3 (en) 2008-05-07 2015-03-04 Univ California Therapeutic replacement and enrichment of ocular surface lubrication
EP2294184A4 (en) 2008-06-30 2013-03-06 Mesoblast Inc Treatment of eye diseases and excessive neovascularization using a combined therapy
US20100087899A1 (en) 2008-10-03 2010-04-08 Danny Erez Skin treatment using variable rf
US8882757B2 (en) 2008-11-11 2014-11-11 Avedro, Inc. Eye therapy system
USD614774S1 (en) 2008-12-18 2010-04-27 Tearscience, Inc. Ocular imaging apparatus
JP2010155012A (en) 2009-01-03 2010-07-15 Therath Medico Kk Eye mask
DE102009014976B3 (en) 2009-03-30 2010-06-02 Jutta Munz Applicator device for applying e.g. cream on eye portion of human body, has activator device provided in upper housing part, and producing heat or coldness that is transmitted to substance contained in substance chamber
EP2506843A4 (en) 2009-12-02 2013-04-17 Bridge Pharma Inc Treating xerophthalmia with compounds increasing meibomian gland secretion
CA2787114A1 (en) 2010-01-11 2011-07-14 Gtx, Inc. Methods of treating meibomian gland dysfunction
US8309852B2 (en) 2010-02-24 2012-11-13 Honeywell International Inc. Dual acting strain relief apparatus
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
TWM386892U (en) 2010-04-07 2010-08-21 Cheng-Chuan Yang Eye massager
USD645565S1 (en) 2010-06-16 2011-09-20 Walton F. Smith Device for stimulating the meibomian glands of the eyelid
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20130046367A1 (en) 2011-08-18 2013-02-21 Willie Ying-Wei Chen Lipid Removal Device for Treating Blepharitis (Meibomian Gland Dysfunction)
US8491508B2 (en) 2010-09-15 2013-07-23 Walton F. Smith Device and method for stimulating the meibomian glands of the eyelid
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
CN102204854B (en) 2010-12-23 2013-02-06 厦门松霖科技有限公司 Device for treating blocking of eye meibomian gland
US20120209154A1 (en) 2011-02-10 2012-08-16 Williams Iii Riley J Hot and cold therapy device
JP5856385B2 (en) 2011-04-08 2016-02-09 株式会社トプコン Ophthalmic image analysis device and ophthalmic image analysis program
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
JP2014518275A (en) 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド Method for treating recurrent meibomian gland disorders and method for reducing the frequency of relapse thereby
WO2013006574A1 (en) 2011-07-01 2013-01-10 Vanderbilt University Surfactant ported device for treatment of blepharitis and applications of same
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
WO2013036894A2 (en) 2011-09-08 2013-03-14 Biolase, Inc. Methods for treating eye conditions
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
JP2015509022A (en) 2012-02-03 2015-03-26 アイ コンフォート リミテッド Eye massager
US9931031B2 (en) 2012-02-21 2018-04-03 Massachusetts Eye & Ear Infirmary Meibomian gland dysfunction
CN102600008B (en) 2012-03-26 2014-05-14 彭荣梅 Meibomian gland massager
CA2869408C (en) 2012-04-05 2021-02-02 Matthew BUJAK Method, system and use for therapeutic ultrasound
WO2013166353A1 (en) 2012-05-04 2013-11-07 Alcon Research, Ltd. Method for diagnosing dry eye and meibomian gland disease using meibomian secretions
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9039718B2 (en) 2012-07-24 2015-05-26 Blephex, Llc Method and device for treating an ocular disorder
CA2878078A1 (en) 2012-07-25 2014-01-30 Rolando TOYOS Selected light wavelengths and delivery devices for the prevention and treatment of dry eye syndrome
CN104470513B (en) 2012-09-28 2015-12-23 参天制药株式会社 The treatment of meibomian gland dysfunction or tarsal glands blocking or preventive
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
WO2014179356A1 (en) 2013-04-30 2014-11-06 Tear Film Innovations Llc Systems and methods for the treatment of eye conditions
CA2911294C (en) 2013-05-03 2022-08-30 Tearscience, Inc. Eyelid illumination systems and methods for imaging meibomian glands for meibomian gland analysis
WO2014184677A2 (en) 2013-05-08 2014-11-20 Optometric Technology Group Ltd. Eye care devices and methods
US10130507B2 (en) 2013-08-03 2018-11-20 Michael C. Whitehurst Dry eye treatment device
CA2871205A1 (en) 2013-11-15 2015-05-15 Matthew BUJAK Method, system and use for therapeutic ultrasound
US10314763B2 (en) 2013-12-31 2019-06-11 Teeny Clean, Llc Eyelid care appliance
CN103816033B (en) 2014-03-19 2016-03-16 中国人民解放军第二军医大学 Eyelid masseur
CN103948490B (en) 2014-03-19 2016-03-16 中国人民解放军第二军医大学 Hand-held eyelid masseur
WO2015163821A1 (en) 2014-04-23 2015-10-29 Singapore Health Services Pte Ltd Monitoring and/or detecting meibomian gland dysfunction
AU2015255813B2 (en) 2014-05-09 2020-02-27 Ocusoft, Inc. Systems, methods, and kits for cleansing an ocular region
AU2015338891B2 (en) 2014-10-30 2021-02-18 Alcon Inc. Systems and methods for the treatment of eye conditions
US20160120692A1 (en) 2014-11-03 2016-05-05 Vicki Min Chen Self-Warming Hands Free Eye Compress
CN104398234B (en) 2014-12-19 2016-08-17 厦门大学 A kind of ocular synthesis analyzer based on specialist system
CN107427459A (en) 2015-02-24 2017-12-01 伊利诺伊大学董事会 For treating the method and composition of scheroma and other ophthalmology diseases
US11103417B2 (en) 2015-04-30 2021-08-31 Lillie A. Mosaddegh Meibomian gland roller
US20190029878A1 (en) 2015-06-18 2019-01-31 Eyedetec Medical, Inc. Moldable heater with miniature harmonic resonance frequency vibration generator for opthalmic eyelid therapy
US20170014300A1 (en) 2015-06-18 2017-01-19 Eyedetec Medical, Inc. Moldable heater with Miniature Resonant Frequency Vibration Generator for Ophthalmic Eyelid Therapy
ITUB20154761A1 (en) 2015-10-29 2017-04-29 Resono Ophthalmic S R L ELECTRODE SYSTEM AND ITS RELATIVE DEVICE FOR THE TREATMENT OF EYE PATHOLOGIES, IN PARTICULAR OF THE DRY EYE
WO2017100608A1 (en) 2015-12-11 2017-06-15 Sight Sciences, Inc. Combination treatment systems
US11826279B2 (en) 2016-03-08 2023-11-28 Ken DauSchmidt Eyelid treatment device and associated methods
CA3019349A1 (en) 2016-04-14 2017-10-19 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
KR101774161B1 (en) 2016-06-27 2017-09-01 동국대학교 산학협력단 Fusion device for image diagnosis and treatment of meibomian gland dysfunction
KR101806298B1 (en) 2017-04-18 2017-12-07 조귀형 Device for massaging meibomian gland around eyes

Patent Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006945A (en) * 1910-07-22 1911-10-24 James D Houston Eye-bathing mask.
US1924315A (en) * 1930-08-27 1933-08-29 Edward C Hemphill Sleep eye shade
US2891252A (en) * 1956-06-01 1959-06-23 Lazo Mario Sleeping device
US3333586A (en) * 1966-11-14 1967-08-01 Bellis Ted Eye-care devices
US4261364A (en) * 1979-01-26 1981-04-14 Haddad Heskel M Electric warm compress for ophthalmic treatment
US4778457A (en) * 1986-11-06 1988-10-18 York Kenneth K Disposable applicator
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4883454A (en) * 1987-09-04 1989-11-28 Sol Hamburg Eyelid and anterior orbit swab
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5151100A (en) * 1988-10-28 1992-09-29 Boston Scientific Corporation Heating catheters
US5368591A (en) * 1988-10-28 1994-11-29 Prutech Research And Development Partnership Ii Heated balloon catheters
US4955377A (en) * 1988-10-28 1990-09-11 Lennox Charles D Device and method for heating tissue in a patient's body
US5343561A (en) * 1989-08-17 1994-09-06 Adamo Ren E Sleeping mask and neck rest
US5158082A (en) * 1990-08-23 1992-10-27 Spacelabs, Inc. Apparatus for heating tissue with a photoplethysmograph sensor
US5030214A (en) * 1990-11-01 1991-07-09 Larry Spector Ocular delivery system
US5425380A (en) * 1991-05-31 1995-06-20 Kimberly-Clark Corporation Surgical eye mask
US5251627A (en) * 1991-06-27 1993-10-12 Morris Donald E Non-invasive measurement of eyeball pressure using vibration
US5283063A (en) * 1992-01-31 1994-02-01 Eagle Vision Punctum plug method and apparatus
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US6423018B1 (en) * 1992-06-19 2002-07-23 Augustine Medical, Inc. Normothermic tissue heating wound covering
US6213966B1 (en) * 1992-06-19 2001-04-10 Augustine Medical, Inc. Normothermic tissue heating wound covering
US6113561A (en) * 1992-06-19 2000-09-05 Augustine Medical, Inc. Normothermic tissue heating wound covering
US5964723A (en) * 1992-06-19 1999-10-12 Augustine Medical, Inc. Normothermic tissue heating wound covering
US5368582A (en) * 1992-08-10 1994-11-29 The Schepens Eye Research Institute Method and apparatus for introducing fluid material into an eye
US6425888B1 (en) * 1994-08-30 2002-07-30 R. P. Scherer Corporation Ocular treatment device
US5601548A (en) * 1994-11-07 1997-02-11 Ophthalmic International, L.L.C. Open angle glaucoma treatment apparatus and method
US5720773A (en) * 1995-01-09 1998-02-24 Lopez-Claros; Marcelo Enrique Method for treating biopsychiatric disorders
US5643336A (en) * 1995-01-09 1997-07-01 Lopez-Claros; Marcelo Enrique Heating and cooling pad
US6153607A (en) * 1995-12-04 2000-11-28 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
US5700238A (en) * 1996-07-25 1997-12-23 Hyson; Morton Isaac Device and method for treatment of headache
US7123968B1 (en) * 1996-09-20 2006-10-17 The Board Of Regents Of The University Of Texas System Heat treatment of inflamed tissue
US5836927A (en) * 1996-10-07 1998-11-17 Fried; George Device to aid in the self administration of eyedrops
US6860880B2 (en) * 1997-03-05 2005-03-01 The Trustees Of Columbia University In The City Of New York Electrothermal instrument for sealing and joining or cutting tissue
US6110292A (en) * 1997-08-12 2000-08-29 Warren R. Jewett Oscillating liquid jet washing system
US20030139790A1 (en) * 1997-08-13 2003-07-24 Surx, Inc. Noninvasive devices, methods, and systems for shrinking of tissues
US5807357A (en) * 1997-08-19 1998-09-15 Kang; Meng-Che Compact nebulizer for treating the eyes
US6482203B2 (en) * 1997-09-30 2002-11-19 Scimed Life Systems, Inc. Deflectable interstitial ablation device
US6193740B1 (en) * 1997-12-19 2001-02-27 Andrea Janine Rodriguez Eye pillows with adjustable strap
US7004942B2 (en) * 1998-01-14 2006-02-28 Solarant Medical, Inc. Ribbed electrodes and methods for their use
US6024095A (en) * 1998-04-10 2000-02-15 Proteus Therapeutics, Inc. Corneal heat and stretch method and apparatus
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US20030114426A1 (en) * 1998-05-08 2003-06-19 Pflugfelder Stephen C. Method for treating meibomian gland disease
US20060154901A1 (en) * 1998-05-08 2006-07-13 Pflugfelder Stephen C Methods for treating ocular rosacea
US6112900A (en) * 1998-07-01 2000-09-05 Ocusoft, Inc. Care kit for contact lens wearers
US6206842B1 (en) * 1998-08-03 2001-03-27 Lily Chen Tu Ultrasonic operation device
US6490488B1 (en) * 1998-12-11 2002-12-03 Urologix, Inc. Method of controlling thermal therapy
US20030065277A1 (en) * 1999-01-21 2003-04-03 Chandice Covington Method and apparatus for measuring factors in mammary fluids
US6181970B1 (en) * 1999-02-09 2001-01-30 Kai Technologies, Inc. Microwave devices for medical hyperthermia, thermotherapy and diagnosis
US6438398B1 (en) * 1999-03-05 2002-08-20 The University Of Miami Process and device for measuring tear fluorescein clearance
US20020035345A1 (en) * 1999-05-25 2002-03-21 Beck Jon E. Methods and apparatus for ocular iontophopesis
US6827898B1 (en) * 1999-05-25 2004-12-07 Viacirq, Inc. Hyperthermia method and apparatus
US6925317B1 (en) * 1999-06-11 2005-08-02 Spectrx, Inc. Integrated alignment devices, system, and methods for efficient fluid extraction, substance delivery and other applications
US7001379B2 (en) * 1999-06-25 2006-02-21 Boston Scientific Scimed, Inc. Method and system for heating solid tissue
US6155995A (en) * 1999-08-05 2000-12-05 Lin; Pin-Hung Structure of a multifunctional eye mask
US20010041886A1 (en) * 1999-12-10 2001-11-15 Durkin Anthony J. Method of treating disorders associated with sebaceous follicles
US6974454B2 (en) * 2000-04-27 2005-12-13 Atricure, Inc. Transmural ablation device with thermocouple for measuring tissue temperature
US6788977B2 (en) * 2000-06-20 2004-09-07 Celsion Corporation System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumor
US20020099094A1 (en) * 2000-08-16 2002-07-25 Anderson Richard Rox Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris
US20020111608A1 (en) * 2001-01-18 2002-08-15 George Baerveldt Minimally invasive glaucoma surgical instrument and method
US20020128696A1 (en) * 2001-03-06 2002-09-12 Henry Pearl Apparatus and method for stimulating hair growth
US20030056281A1 (en) * 2001-09-26 2003-03-27 Tokuichiro Hasegawa Eye mask
US20030211043A1 (en) * 2001-09-28 2003-11-13 Korb Donald R. Eye treatment
US20060030604A1 (en) * 2001-11-08 2006-02-09 Magdalena Elsinger Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US6840954B2 (en) * 2001-12-20 2005-01-11 Solarant Medical, Inc. Systems and methods using vasoconstriction for improved thermal treatment of tissues
US6908195B2 (en) * 2002-01-24 2005-06-21 John Robert Fuller Therapeutic eye and eye lid cover
US20040237969A1 (en) * 2002-01-24 2004-12-02 Fuller John Robert Therapeutic eye and eye lid cover
US6882885B2 (en) * 2002-03-19 2005-04-19 Solarant Medical, Inc. Heating method for tissue contraction
US20030195438A1 (en) * 2002-04-12 2003-10-16 Petillo Phillip J. Method and apparatus to treat glaucoma
US6641264B1 (en) * 2002-04-15 2003-11-04 Mary Schwebel Remedy for dry eye syndrome
US7357500B2 (en) * 2002-04-15 2008-04-15 Schwebel Mary L Remedy for dry eye syndrome
US6886933B2 (en) * 2002-04-15 2005-05-03 Mary L. Schwebel Remedy for dry eye syndrome
US6874884B2 (en) * 2002-04-15 2005-04-05 Mary L. Schwebel Remedy for dry eye syndrome
US20060139569A1 (en) * 2002-04-15 2006-06-29 Schwebel Mary L Remedy for dry eye syndrome
US7036928B2 (en) * 2002-04-15 2006-05-02 Schwebel Mary L Remedy for dry eye syndrome
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
US20030233135A1 (en) * 2002-06-14 2003-12-18 Yee Richard W. Method and apparatus for preventing and treating eyelid problems
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US6860852B2 (en) * 2002-10-25 2005-03-01 Compex Medical S.A. Ultrasound therapeutic device
US20060018953A1 (en) * 2002-11-05 2006-01-26 Michel Guillon Eyelid margin wipes comprising chemical means for temperature adjustment
US7108694B2 (en) * 2002-11-08 2006-09-19 Olympus Corporation Heat-emitting treatment device
US20040153093A1 (en) * 2003-01-31 2004-08-05 Advanced Medical Optics, Inc. Bi-manual phacoemulsification apparatus and method
US7118591B2 (en) * 2003-04-17 2006-10-10 The University Of Chicago Heat transfer probe
US20060157064A1 (en) * 2003-07-30 2006-07-20 Suzanne Davison Apparatus, system and method for treating dry eye conditions and promoting healthy eyes
US20050022823A1 (en) * 2003-07-30 2005-02-03 Suzanne Davison Apparatus, system and method for treating dry eye conditions and promoting healthy eyes
US7231922B2 (en) * 2003-07-30 2007-06-19 Suzanne Davison Apparatus, system and method for treating dry eye conditions and promoting healthy eyes
US20070203462A1 (en) * 2003-12-01 2007-08-30 Soroudi Abraham E Device and method for exothermic treatment of eyelid diseases
US20050119629A1 (en) * 2003-12-01 2005-06-02 Soroudi Abraham E. Device and method for exothermic treatment of eyelid diseases
US7211070B2 (en) * 2003-12-01 2007-05-01 Abraham Ebbie Soroudi Device and method for exothermic treatment of eyelid diseases
US20070280924A1 (en) * 2004-03-02 2007-12-06 Julie Daniels Pharmaceutical Preparations For And Treatment Of Ocular Surface and Other Disorders
US20060104914A1 (en) * 2004-03-12 2006-05-18 Soroudi Abraham E Device and method for treatment of eyelid diseases
US20050220742A1 (en) * 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
US20060233859A1 (en) * 2004-04-30 2006-10-19 Allergan, Inc. Methods for treating retinopathy with extended therapeutic effect
US20060183698A1 (en) * 2004-06-07 2006-08-17 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US20080075787A1 (en) * 2004-11-25 2008-03-27 Sawako Hibino Therapeutic Agent For Ophthalmic Diseases
US20070049913A1 (en) * 2005-07-18 2007-03-01 Grenon Stephen M Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US20080051741A1 (en) * 2005-07-18 2008-02-28 Grenon Stephen M Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187310B2 (en) 2005-07-18 2012-05-29 Tearscience, Inc. Method and apparatus for treating gland dysfunction
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US10940074B2 (en) 2005-07-18 2021-03-09 Tearscience Inc Melting meibomian gland obstructions
US10905898B2 (en) 2005-07-18 2021-02-02 Tearscience, Inc. Methods and apparatuses for treating gland dysfunction
US10376273B2 (en) 2005-07-18 2019-08-13 Tearscience, Inc. Methods and apparatuses for treatment of meibomian glands
US9913678B2 (en) 2005-07-18 2018-03-13 Tearscience, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US9719977B2 (en) 2005-07-18 2017-08-01 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US9216028B2 (en) 2005-07-18 2015-12-22 Tearscience, Inc. Apparatuses for treatment of meibomian glands
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US8685073B2 (en) 2005-07-18 2014-04-01 Tearscience, Inc. Apparatus for treating meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20080051741A1 (en) * 2005-07-18 2008-02-28 Grenon Stephen M Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US8628504B2 (en) 2005-07-18 2014-01-14 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US8025689B2 (en) 2005-07-18 2011-09-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US8187311B2 (en) 2005-07-18 2012-05-29 Tearscience, Inc. Method and apparatus for treating gland dysfunction
US8632578B2 (en) 2006-05-15 2014-01-21 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US10952896B2 (en) 2006-05-15 2021-03-23 Tearscience Inc Methods and apparatuses for treatment of meibomian gland dysfunction
US8523928B2 (en) 2006-05-15 2013-09-03 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8617229B2 (en) 2006-05-15 2013-12-31 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
WO2008024100A3 (en) * 2006-08-21 2009-04-30 Tearscience Inc Method and apparatus for treating gland dysfunction
US11110003B2 (en) 2007-11-13 2021-09-07 Mgd Innovations, Inc. Gland or duct diagnostic and treatment methods and related apparatus
US9510844B2 (en) 2007-11-13 2016-12-06 Mgd Innovations, Llc Gland or duct diagnostic and treatment methods and related apparatus
US20100100029A1 (en) * 2007-11-13 2010-04-22 Steven Maskin Gland or duct diagnostic and treatment methods and related apparatus
US20100292630A1 (en) * 2007-11-13 2010-11-18 Maskin Steven L Meibomian Gland Intraductal Diagnostic and Treatment Methods
US10159599B2 (en) * 2007-11-13 2018-12-25 Mgd Innovations, Llc Meibomian gland intraductal diagnostic and treatment methods
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
US8636786B2 (en) 2008-05-16 2014-01-28 Seth A. Biser Thermal compress system and methods of using the same
US11076983B2 (en) 2008-05-16 2021-08-03 Seth A. Biser Thermal eye compress systems and methods of use
US20110178585A1 (en) * 2008-05-16 2011-07-21 Biser Seth A Thermal compress system and methods of using the same
US20120165708A1 (en) * 2009-06-24 2012-06-28 Colin Parsloe Massage Apparatus and Method of Use
US9675516B2 (en) * 2009-06-24 2017-06-13 Innovative Treatment Solutions Ltd. Massage apparatus and method of use
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
US20130110101A1 (en) * 2011-09-08 2013-05-02 Marcia Van Valen Methods for treating eye conditions
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10456298B2 (en) 2013-04-30 2019-10-29 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10092449B2 (en) 2013-04-30 2018-10-09 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US11065152B2 (en) 2013-04-30 2021-07-20 Alcon Inc. Systems and methods for the treatment of eye conditions
US10456294B2 (en) 2013-04-30 2019-10-29 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US10835418B1 (en) 2016-09-06 2020-11-17 Sarah S. Darbandi Meibomian gland thermal treatment apparatus
US10603210B1 (en) 2017-02-02 2020-03-31 Mgd Innovations, Llc Meibomian gland probing with blood product injection
CN113164283A (en) * 2018-12-06 2021-07-23 爱尔康公司 Systems and methods for treating eye conditions

Also Published As

Publication number Publication date
US8083787B2 (en) 2011-12-27
US8685073B2 (en) 2014-04-01
US8187311B2 (en) 2012-05-29
US8187310B2 (en) 2012-05-29
US20110137214A1 (en) 2011-06-09
US20150283402A1 (en) 2015-10-08
US20100256552A1 (en) 2010-10-07
US20070016254A1 (en) 2007-01-18
US20190224497A1 (en) 2019-07-25
US20080109052A1 (en) 2008-05-08
US8025689B2 (en) 2011-09-27
US20120016275A1 (en) 2012-01-19
US10905898B2 (en) 2021-02-02
US20070016255A1 (en) 2007-01-18
US8915253B2 (en) 2014-12-23
US9060843B2 (en) 2015-06-23
US20110130729A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
US10905898B2 (en) Methods and apparatuses for treating gland dysfunction
EP2056753B1 (en) Apparatus for treating gland dysfunction
US20190282251A1 (en) Methods and apparatuses for treatment of meibomian glands
US20170299567A1 (en) Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981095B2 (en) Methods for treating meibomian gland dysfunction employing fluid jet
US7833205B2 (en) Methods for treating meibomian gland dysfunction employing fluid jet
US8950405B2 (en) Treatment of obstructive disorders of the eye or eyelid
CN102846423B (en) Apparatus for treating gland dysfunction

Legal Events

Date Code Title Description
AS Assignment

Owner name: KOLIS SCIENTIFIC, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KORB, DONALD R.;WILLIS, TIMOTHY R.;GRAVELY, BENJAMIN T.;AND OTHERS;REEL/FRAME:017994/0625

Effective date: 20060511

AS Assignment

Owner name: TEARSCIENCE, INC., NORTH CAROLINA

Free format text: CHANGE OF NAME;ASSIGNOR:KOLIS SCIENTIFIC, INC.;REEL/FRAME:022061/0054

Effective date: 20090101

Owner name: TEARSCIENCE, INC.,NORTH CAROLINA

Free format text: CHANGE OF NAME;ASSIGNOR:KOLIS SCIENTIFIC, INC.;REEL/FRAME:022061/0054

Effective date: 20090101

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION